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RE´SUME´
Nous avons pre´alablement de´montre´ que l’endothe´line-1 (ET-1), un peptide
vasoconstricteur de 21 acides amine´s, joue un roˆle central dans le me´tabolisme
des tissus articulaires et a des fonctions cataboliques sur le cartilage articulaire
dans l’oste´oarthrose, en liant son re´cepteur de type A (ETA). Suite a` la relaˆche
du nonapeptide vasodilatateur bradykinine (BK), et l’augmentation d’expression
du re´cepteur B1 des kinines (BKB1), ces me´diateurs engendrent un cycle d’in-
flammation, une destruction du cartilage, et une douleur articulaire. Lors de cette
e´tude, l’efficacite´ the´rapeutique des antagonistes spe´cifiques du ETA et/ou BKB1
dans un mode`le animal d’oste´oarthrose a e´te´ teste´e. Notre hypothe`se est que l’an-
tagonisme va diminuer la progression de la pathologie et de la douleur articulaire.
L’oste´oarthrose a e´te´ induite chez des rats par rupture chirurgicale du liga-
ment croise´ ante´rieur. Les animaux ont e´te´ traite´s par injections intra articulaire
hebdomadaires des antagonistes peptidiques spe´cifiques du ETA et/ou BKB1. La
douleur articulaire a e´te´ e´value´e par le test d’incapacitance statique durant les
deux mois postope´ratoires ; la morphologie articulaire a e´te´ examine´e post mor-
tem par radiologie et histologie.
On constate que le traitement a diminue´ la douleur et a pre´serve´ la morphologie
articulaire ; la double inhibition a e´te´ plus efficace que la simple inhibition. En
conclusion, l’antagonisme double d’ETA et BKB1 ame´liore la douleur chronique
et pre´vient la de´gradation articulaire dans l’oste´oarthrose, ce qui sugge`re que ces
re´cepteurs peuvent eˆtre des cibles the´rapeutiques potentiels pour le traitement de
vi
cette pathologie.
Mots cle´s : oste´oarthrose, inflammation, douleur, endothe´line, bradykinine,
mode`le animal, antagoniste peptidique
ABSTRACT
The author’s laboratory has previously shown that endothelin-1 (ET-1), a 21-
residue vasoconstrictive peptide, plays a central role in joint tissue metabolism,
and has a catabolic function in matrix collagen degradation in osteoarthritis.
These effects occur primarily through ligation of the endothelin-1 receptor A sub-
type (ETA). The subsequent release of the nonapeptide vasodilator bradykinin
(BK) in the joint microenvironment, and up-regulation of bradykinin receptor B1
(BKB1) expression, engenders a vicious cycle of synovial membrane inflammation,
articular cartilage destruction, and joint pain. In the present work, we describe
a preclinical study of the efficacy of treatment of surgically induced osteoarthri-
tis with ETA and/or BKB1 specific peptide antagonists. We hypothesize that
antagonism will diminish osteoarthritis progress and articular pain.
Osteoarthritis was surgically induced in rats by transection of the anterior
cruciate ligament. Animals were subsequently treated with weekly intra-articular
injections of specific peptide antagonists of ETA and BKB1. Hind limb pain
was measured by the static weight bearing test for two months post-operatively.
Post-mortem, knee joints were analyzed radiologically and histologically.
Local antagonist treatment diminished overall limb pain, and accelerated post-
operative recovery, after disease induction. Treatment also protected joint ra-
diomorphology and histomorphology, with dual antagonism being slightly more
protective.
ETA and BKB1 dual antagonism improves chronic pain and prevents joint
viii
degradation in osteoarthritis. They therefore represent a novel therapeutic target:
specific receptor dual antagonism may prove beneficial in disease management.
Key words: osteoarthritis, inflammation, pain, endothelin, bradykinin, ani-
mal model, peptide antagonist
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CHAPTER 1
INTRODUCTION
Osteoarthritis (OA), a disorder also known as degenerative joint disease or
degenerative arthritis, is the most frequent joint disease in seniors. It is the most
common form of arthritis, affecting more than 10% of adult Canadians [39]. Most
often involving the hands and the large weight-bearing joints (hips, knees, back),
OA is clinically characterized by the progressive destruction of articular cartilage,
subchondral bone remodelling, osteophyte formation, and synovial membrane in-
flammation; the pathophysiological mechanisms responsible for these changes are
not yet completely understood [79]. This leads to joint pain, which in turn leads
to reduced physical activity and thereby raises the risk of other diseases. In severe
cases, joint replacement surgery is necessary, which represents a major health-care
burden: this approach has significant morbidity and is extremely expensive. Cur-
rent treatment only alleviates symptoms, and does not attack the basic biological
causes of the disease. It is therefore of paramount importance to understand the
molecular and cellular causes of OA pathogenesis, in order to establish specific
therapies.
The author’s laboratory has previously demonstrated that the vasoconstrictor
peptide endothelin-1 (ET-1) plays a central role in joint tissue metabolism, and
has a catabolic function in matrix collagen degradation in osteoarthritis [109, 132,
187]. These effects occur primarily through ligation of the endothelin-1 receptor
2A subtype (ETA) [110, 124, 144]. The subsequent release of the nonapeptide
vasodilator bradykinin (BK) in the joint microenvironment, and up-regulation of
bradykinin receptor B1 (BKB1) expression, engender a cycle of synovial membrane
inflammation, articular cartilage destruction, and joint pain [142, 189, 206]. We
hypothesize that blocking these receptors with specific antagonists will ameliorate
disease state and slow OA pathogenesis. This thesis deals with the therapeutic
potential of such an approach.
In the literature review, we provide a basic overview of OA, a summary of clas-
sic inflammatory processes, and a discussion of the role of endothelial molecules in
the context of joint inflammation and pain. We then discuss current experimental
approaches to model OA in laboratory animals, with a focus on assessing joint
pain. The experimental work described is a preclinical study, in the form of a
submitted article manuscript (with an expanded methods section as a separate
chapter), where surgically induced OA was treated by local injections of ETA
and/or BKB1 specific peptide antagonists. We then discuss our results in light
of current work in the field, along with limitations of our study and suggested
experimental work. We conclude with a general interpretation of our results and
suggest two avenues for further research.
CHAPTER 2
LITERATURE REVIEW
2.1 Osteoarthritis
2.1.1 Disease overview
Osteoarthritis (OA) is a joint pathology defined as the progressive destruction
of articular cartilage, accompanied by subchondral bone remodelling, osteophyte
formation, and synovial membrane inflammation [79]. Clinically, this disease pro-
gresses slowly and principally affects the hands and large weight-bearing joints.
Functional limitations ensue and cause significant morbidity: symptomatic OA
reduces quality of life [150] and can contribute to emotional distress. Patients
end up engaging in adaptive behaviours [80], such as avoiding exercise, which
negatively impact overall health.
OA also engenders a significant economic burden with direct patient-based
costs, such as medication, hospitalization, and surgery, along with indirect costs
from loss of productivity [4]. In a large US meta-analysis of health care costs,
[114], out-of-pocket expenditures increased by $1 379 (women) and $694 (men)
per annum for OA patients. Aggregated expenditures over the study period were
$185.5 billion per annum (2007 US dollars), two-thirds of which are due to women’s
OA; the reported female-to-male disease ratio varies between 1.5 and 4 [10].
42.1.2 Prevalence and incidence
Prevalence, defined as the proportion of diseased individuals in a given popu-
lation at a particular time point, and incidence, defined as the rate of new cases
per time period in a given population, are two epidemiological measures of disease
penetrance [120]. According to Arden and Nevitt [10], “OA is the most common
joint disorder in the world.” Jordan et al. [104] report a UK prevalence rate of
knee OA at 18.1% over a 55-year study period. Hip and hand OA are much less
common, with prevalence estimates ranging from 0.7-4.4% for the hip and roughly
2.5% for the hand. Oliveria et al. [161] report an age- and sex-standardized inci-
dence of 240 cases of knee OA, 88 cases of hip OA, and 100 cases of hand OA, all
per 100 000 person-years; new cases tended to plateau at around 80 years for both
men and women. Both these measures track symptomatic OA: almost all humans
will develop detectable “radiographic” OA [18, 33] or have cartilage damage on
autopsy [10] as part of natural aging, but only some patients require treatment
for joint pain. The reasons for this disparity are still poorly understood.
2.1.3 Risk factors
OA has several characterized risk factors that contribute in concert to patho-
genesis. Increasing age is the risk factor most strongly correlated with OA. On a
biomechanical level, this may arise from proprioceptive changes, decreased muscle
tone, and altered gait. On a cellular level, chondrocytes may become less able
to repair the tissue, due to decreased ability to synthesize cartilage components,
decreased responsiveness to growth factors, and increased apoptosis [2].
5Obesity is also strongly correlated with OA: a higher body mass index stresses
the joints beyond healthy biomechanical limits, which results in altered loading
and joint degeneration [97]. Joint overuse can have similar effects: elite athletes
have increased rates of hip, knee, and ankle OA, relative to the general population
[115]. High-level sports can also predispose athletes to OA due to injury: to cite a
personal example, this author had both anterior cruciate ligaments reconstructed
with associated medial meniscectomies due to basketball injuries. This interven-
tion carries with it an increased risk of knee problems (Ronald A. Dimentberg
MDCM, patient consultation): meniscus and ligament injuries can predispose pa-
tients to knee OA [108, 140]. As noted above in subsection 2.1.2, women, especially
over the age of 50, report 1.5 to 4 times as much OA as men [10]. The reasons
for this difference in disease ratio are poorly understood: it has been ascribed to
oestrogen deficiency [223], since oestrogen can up-regulate proteoglycan synthe-
sis [178]. Nonetheless, the evidence is currently inconsistent, with no prospective
randomized clinical trials [2, 157].
OA has a strong genetic component: Zhai et al. [233] have reported 50-65%
disease concordance between identical twins. While specific genes responsible
have been difficult to identify due to the different manifestations of the disease,
several candidate genes have been identified that most likely have additive effects
[209]. Point mutations in types II, IV, V, and VI collagens, as well as cartilage
oligomeric matrix protein (COMP) [145, 176] have been correlated with early-
onset OA. Genome-wide linkage analyses have identified several pro-inflammatory
genes that correlate with knee OA, such as the interleukin-1 (IL-1) genes IL-1
6alpha (IL1A), IL-1 beta (IL1B), and IL-1 receptor antagonist (IL1RN ) [125],
along with a cyclooxygenase-2 (PTGS2 ) variant [210].
2.1.4 Symptomatology
OA is characterized by low-grade joint pain, which is the major criterion in
the American College of Rheumatology disease classification [5]. This pain leads
to functional limitation (as discussed above in section 2.1.1), and is the main
complaint motivating patient presentation [60, 65]. Its aetiology is multifactorial:
subchondral bone can have microfractures or symptomatic medullary hyperten-
sion, osteophytes can cause stretching of periosteal nerve endings, ligaments may
be stretched, the joint capsule can be inflamed or distended, the synovium may
be inflamed, and muscles may spasm [137]. Furthermore, neoinnervation of joint
tissue concurrent with angiogenesis [13, 28] may contribute to deep joint pain.
Articular degeneration in OA is progressive in nature: early cartilage roughening
and subchondral bone sclerosis is followed by deepening cartilage fissuring and
bone remodelling in the intermediate stage of degeneration. End-stage joint de-
generation involves complete loss of articular cartilage, osteophyte formation, and
subchondral cysts. These are accompanied by synovitis, which can be primary
and/or reactive. Severe osteophytes are palpable and/or visible upon physical
examination of the joint, along with crepitus [164].
72.1.5 Diagnosis
Diagnosis of OA follows established criteria, with minor differences for each
joint system being assessed. Common themes are joint pain, restricted move-
ment, bony enlargement, and reduced function. To take the example of knee OA:
the most recent set of guidelines to be published are the 2010 EULAR (Euro-
pean League Against Rheumatism) recommendations [235]. They require three
symptoms, namely persistent knee pain, limited morning stiffness, and reduced
function, along with three signs: crepitus, restricted movement, and bony enlarge-
ment. These criteria have a sensitivity of 99% when all six are present. They are
similar to the 1986 American College of Rheumatology criteria [5], which require
three of the following six criteria: patient over 50 years old, morning joint stiffness,
crepitus, bony tenderness, enlargement, and absence of palpable warmth.
Radiological evidence of joint degradation is often sought by X-ray, to measure
joint space narrowing, and to visualize subchondral bone remodelling and osteo-
phyte formation. Magnetic resonance (MR) imaging can be used to assess soft-
tissue damage: cartilage lesions, muscle deficiencies, ligament tears, and meniscal
problems in the case of the knee. This information can confirm diagnostic findings
as established by evidence-based criteria. However, as we discuss above in sub-
section 2.1.2, such radiological evidence, especially X-ray findings, are sometimes
a sign of normal aging, rather than of joint disease: symptomatic or painful OA
is the condition that necessitates intervention.
Pain assessment of OA patients is primarily performed via self-administered
8questionnaires such as the McGill Pain Questionnaire [143] or the Western Ontario
and McMaster Universities Osteoarthritis Index [19, 139], which score perceived
pain and functional limitations. These questionnaires must be statistically vali-
dated to be used in clinical practice [166]. A visual analogue scale or a simple
pain rating (“On a scale of 1 to 10. . . ”) may provide the patient and clinician with
a relatively simple and intuitive manner to communicate perceived pain: logging
such scores over time may yield patterns of pain sensation.
Biomechanical functional tests, both qualitative and quantitative, are em-
ployed as well. Mechanical sensitivity of the joint can be assessed: OA patients
have lower thresholds for cutaneous pain than healthy controls [93]. Range of mo-
tion and gait can be analyzed and quantified with an anatomical protractor, or by
using external markers attached to anatomical reference points [211]. OA patients
have reduced range of motion in affected joints [103] due to deep joint pain. Static
weight bearing can be measured using a force platform which provides a map of
foot pressure; this can be used to discern weight bearing changes in OA patients
as they shift weight off the affected joint(s) [116].
The gold standard for biomechanical assessment is computerized motion anal-
ysis [78], where external markers are placed on anatomical reference points to
track the limbs, and force sensor arrays quantify the force applied by the feet on
the ground, or by the hands on the wall, depending on the test paradigm. In knee
OA patients, walking speed, stride cadence and length are all reduced, along with
knee flexion and swing phases. Peak applied forces are also lower. Stride time
and overall stance phase are lengthened. All these alterations indicate that the
9patients are engaging in adaptive behaviours due to their joint pain.
2.1.6 Treatment
Current OA treatments are almost all symptomatically based [6], since there
is no known cure. That being the case, OA is medically managed with three main
treatment modalities: non-pharmacologic, pharmacologic, and surgical. The al-
gorithm for applying each of these strategies is based on successive recourse to
more and more invasive treatments as necessary (Figure 2.1). Obesity and joint
mechanics are the risk factors for OA that are most amenable to non-invasive inter-
vention [97]. Weight loss programs, coupled with patient education and support,
are the first lines of defence against OA functional limitations. Epidemiological
research has shown that monthly telephone contact with trained social services
personnel can improve patient well-being and functioning without significant cost
increases [220]. Physical therapy can strengthen periarticular muscles and joint
range of motion, thereby improving joint function. Occupational therapy can en-
sure proper joint protection, energy conservation, and effective adaptive strategies,
such as cane or crutch use. Adherence to a program of both aerobic and strength
training exercise has been directly correlated to improvements in joint pain and
overall functioning [63]. Such non-pharmacologic measures “are the cornerstone
of OA management” [6] and are continued even if other treatment modalities are
subsequently adopted.
Current pharmacologic approaches for OA patients are essentially pain man-
agement strategies. While a disease-modifying OA drug (DMOAD) [170, 221] is
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the ne plus ultra of OA pharmacologic research, the as of yet incomplete under-
standing of OA pathogenesis makes this goal difficult to attain. There is a need
for a novel pharmacological approach to OA treatment: further understanding of
the molecular mechanisms behind OA pathogenesis and progression should pro-
vide avenues towards targeted disease-modifying or -slowing treatments [3, 133].
Treatments in current clinical use for OA pain are the same as for any other
chronic pain condition: analgesics (including NSAIDs and COX-2 inhibitors), cor-
ticosteroids, and so forth. These treatments are not without significant side-effect
profiles: much of the task of the rheumatologist is to manage sequelae, such as
steroid tolerance and/or gastrointestinal effects [234]. Opioids are discouraged due
to the high possibility for dependence, unless the pain is severe and intractable
with other agents [4, 6]. Oral supplements of cartilage matrix components such
as glucosamine sulphate and chondroitin sulphate have been prescribed for pain
relief in moderate OA [234], but a recent network meta-analysis of 10 clinical tri-
als (3803 patients in total) by Wandel et al. [215] calculated that there was no
clinically relevant effect of such treatment on perceived joint pain or on joint space
narrowing. Viscosupplementation by intra-articular injection with hyaluronic acid
is offered by some clinicians, but there is debate about its efficacy. In Quebec,
the Agence d’e´valuation des technologies et des modes d’intervention en sante´
does not currently recommend that it be covered by Medicare, due to the lack of
conclusive evidence [50].
Surgical interventions for OA are considered treatments of last recourse, due
to their high degree of invasiveness and increased cost, relative to non-surgical
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modalities. They are quite effective: patients report significant improvements in
function and reduction in joint pain within the year after surgery [234]. There
are three main surgical options: osteotomy, partial or total joint replacement,
and joint fusion [128, 234]. Osteotomy, defined as the surgical cutting of bone, is
performed in OA in order to realign the affected joint such that the weight load is
redistributed on unaffected joint compartments [48, 100]. While this does not cure
the disease, it can delay total joint replacement, and is therefore recommended for
young active patients who are not (yet) suitable for total joint replacement [128].
Joint arthroplasty involves removing the affected joint or joint compartment(s)
and replacing them with prosthetic implants, usually made of polyethylene and
cobalt-chrome-molybdenum alloy [55]. This treatment removes the diseased tis-
sue: as such, it is quite effective at restoring function and alleviating joint pain
[158]. The main drawback to joint replacement is that the implants only last 10-
15 years, which can necessitate multiple surgeries, especially in patients younger
than 50 years at the time of initial joint replacement [95]: this may be due to the
increased joint use of younger patients. Joint arthrodesis or fusion, the treatment
of choice before joint replacement became technically feasible, is only performed
presently when joint replacement has failed and the joint is surgically unrecon-
structable. This usually occurs when a joint arthroplasty site becomes infected
[47].
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Figure 2.1: Flow chart depicting current therapeutic options for osteoarthritis. Once a diagnosis
of OA is confirmed, non-pharmacologic interventions are started, as described above in subsection
2.1.6. If not effective at reducing pain, pharmacologic options, most often multimodal, are initiated.
Joint arthroplasty is used as a last resort. Adapted from Altman [4].
2.1.7 Pathobiology
In early OA, extracellular matrix (ECM) components are structurally com-
promised. Chondrocytes and synoviocytes (synovial fibroblast-like cells) play a
key role in this process, mainly by producing abnormally high levels of proteolytic
enzymes. In advanced OA, this results in the complete loss of articular cartilage
and in the formation of large lesions with bone exposure, along with subchondral
bone remodelling. The associated gross and histological findings are well charac-
terized, with cartilage fissures, loss of proteoglycans, osteophyte formation, and
fibrosis [168]. This destruction is a hallmark of the failure of articular chondro-
cytes to maintain a homeostatic balance between ECM synthesis and degrada-
tion [54, 137]. Various factors, released from both cartilage and synovial mem-
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brane, are involved in this process: aggrecanases, specifically ADAMTS-4 and
ADAMTS-5; matrix metalloproteinases (MMPs), specifically MMP-1 (intersti-
tial collagenase) and MMP-13 (collagenase 3); pro-inflammatory cytokines, such
as IL-1β and TNF-α; growth factors, such as TGF-β-1; and nitric oxide (NO)
[54, 135, 159, 175]. Among these, MMPs appear to play a critical role, as they
are capable of degrading cartilage ECM components such as type II collagen and
proteoglycans [24, 175]. The degradation products of articular collagen are type
II collagen neoepitopes, which act as specific markers of joint disease, since they
are found in the synovial fluid and urine of OA patients [44, 71]. Regulation of
MMP gene expression and protein production involves several factors, including
cytokines and growth factors [148, 175]: IL-1β stimulates the synthesis and se-
cretion of MMPs and urokinase-type plasminogen activator (u-PA) [76]. Enzyme
inhibitors such as tissue inhibitor of metalloproteinases (TIMP) and plasminogen
activator inhibitor (PAI) regulate the balance of latent and active degradative
enzymes; these inhibitors are controlled by TGF-β1 [2].
Aggrecanases are extracellular proteases that degrade aggrecan by cleaving at
the glutamine373-alanine374 site; they are part of a protein family known as the
A Disintegrin-like And Metalloprotease domain (reprolysin-type) with Throm-
boSpondin type I motif (ADAMTS) [203]. ADAMTS-4 and ADAMTS-5 (also
known as aggrecanases 1 and 2) are implicated in cartilage destruction in OA
[12]. ADAMTS-4 is specifically up-regulated in OA synovium, and is induced by
TGF-β1. ADAMTS-5 is constitutively expressed by synoviocytes, but is found in
a truncated form (53-kDa instead of the normal 70-kDa form) in arthritic synovial
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tissue: this may be due to alternative post-translational processing that is only
active in a chronically inflamed joint [225].
Subchondral bone sclerosis is a sign of advanced OA. This may occur due
to neoangiogenesis in the basal layers of degenerating cartilage, or as a result
of abnormal healing of microfractures [75]. TGF-β1 is expressed in osteophytes
[207], and may potentiate abnormal bone growth in OA. Subchondral bone can
also have bone marrow lesions, as detected on MR [66]. While the implications for
OA pathogenesis are unclear, it has been suggested that other tissue abnormalities
such as cysts and avascular necrosis lead to the lesions seen on MR [2].
Classically, synovial inflammation was viewed as secondary or incidental to
cartilage destruction in OA. However, recent findings have highlighted the role
of primary synovial inflammation in OA pathogenesis [14]. Synovial hypertrophy
and hyperplasia can occur asymptomatically early in OA, along with lymphocytic
infiltration [22]. Pro-inflammatory mediator release from articular chondrocytes,
along with cartilage breakdown products, can result in degradative enzyme release
from the synovial membrane, thus aggravating the disease [181]. Most impor-
tantly, the synovial membrane produces IL-1β and TNF-α, which contribute to
the pro-inflammatory and degradative processes in OA [2]. In sum, the release of
pro-inflammatory and degradative mediators in the joint microenvironment con-
tribute to tissue catabolism and inflammation (Figure 2.2), which then causes the
joint pain characteristic of the disease (as discussed in subsection 2.1.4).
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Figure 2.2: Biochemical basis of OA. Schematic overview of degradative mediators in joint microen-
vironment (A) and details of catabolic pathways (B). Adapted from Martel-Pelletier and Pelletier
[136]. c©2001 CORE Health Services Inc., all rights reserved.
16
2.2 Inflammatory pain in OA
Arthritis is literally translated from the Latin as“inflammation of a joint”[164].
Inflammation in OA is now viewed as a central disease process [14]. It is the first
step in a vicious cycle of joint pain, tissue damage, and further inflammation: as
discussed above in subsection 2.1.7, synovial inflammation can be primary and/or
reactive in OA, with multifactorial aetiology. As such, it can be examined in the
context of inflammatory responses, which have common mechanisms in a wide
variety of conditions. We briefly discuss generalities of inflammation, and focus
on the pro-inflammatory roles of endothelial molecules in joint tissue.
2.2.1 Inflammation
Inflammation is the set of physiological responses of tissue to harmful stimuli,
such as infection and tissue injury [117, 131]. Designed to remove the stimulus
and initiate repair, inflammation is most likely an adaptive response to restore
tissue homeostasis. There are four main components of an inflammatory path-
way: inducers, sensors, mediators, and effectors; each acts in turn. Inducers are
the initial cause of an inflammatory response, and sensors are those receptors
or circulating factors that respond to the inducers. Mediators are the factors,
produced downstream to sensor activation, that affect the tissues and systems
in the inflammatory environment, and effectors are the cells and tissues that are
specifically affected by the inflammatory response [141].
The inflammatory response is best understood in the context of immune re-
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sponses to exogenous pathogens, where innate immune receptors on tissue macro-
phages and mast cells are triggered by pathogen-associated molecular patterns
[17]. Ligation of these receptors leads to the production of chemokines, cytokines,
vasoactive amines, eicosanoids, and other inflammatory mediators. These medi-
ators affect vascular wall permeability, allowing plasma proteins and leukocytes
to access the inflammation site. Elimination of the pathogen is followed by a re-
pair phase, where macrophages secrete anti-inflammatory mediators and growth
factors [194, 195]. If this acute response fails to clear the infection, the adaptive
immune system, in the form of macrophages and T cells, is recruited and acti-
vated. Chronic inflammation results when pathogen clearance is unsuccessful, and
often leads to tissue destruction [61].
According to Medzhitov [141], while other types of inflammation share many
of the characteristics of infection-induced inflammation, the mechanisms that
regulate such inflammation, along with their physiological roles, are unclear.
In particular, they do not appear to fit the stereotypical patterns of acute-to-
chronic progression as described above. Nonetheless, examination of the nature
of endogenously-induced inflammation can shed light on many pathophysiological
responses. (We do not discuss non-microbial exogenously induced inflammation,
such as allergic inflammation, since it is beyond the scope of this work.)
Endogenous inducers of inflammation can take many forms, but all are sig-
nalling molecules produced by malfunctioning tissue. Many of these inducers are
substances that are only produced upon tissue breakdown, or are only present in a
given tissue compartment that is normally sequestered from the vascular system.
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For example, hyaluronante, an ECM component that is normally a high-molecular-
weight polymer, breaks down into fragments that are pro-inflammatory. These
fragments provoke tissue repair in a reactive-oxygen-species-dependent manner
[101, 102]. Another classic example is that of collagen (inducer), an ECM com-
ponent that is normally sequestered from plasma, activates coagulation factor
XII (sensor) upon rupture of the endothelial wall. Activated factor XII initi-
ates, among others, the kallikrein-kinin system, which produces the vasodilator
bradykinin (BK) (mediator), which acts on the vasculature and smooth muscle
cells (effectors), as well as stimulating pain sensation [141]. (We discuss BK in the
context of joint tissue below in subsection 2.2.8.) Chronic inflammation occurs
in the same manner as with exogenous inducers, in that the acute inflammatory
response fails to clear the noxious stimulus.
Clinically, inflammation is described by the four cardinal signs of Celcus (1st
century AD): rubor et tumor cum calore et dolore (redness and swelling with heat
and pain) [20, 179]. These signs are not exclusive: to quote Stedman’s Medical
Dictionary [58], “all the above signs may be observed in specific instances, but no
single sign must, as a matter of course, be present.” Moreover, an inflammatory
process may be clinically undetectable, yet may be causing some of the cellular
processes responsible for the cardinal signs, and tissue may be affected by pro-
inflammatory mediators in the absence of inflammatory cell infiltration. Thus,
many authors currently argue for a multi-modal and complex view of inflamma-
tion, in that it is not a single process but a collection of responses to trauma
or infection, and that it is not binary (on-off) in nature, being influenced by a
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multitude of extrinsic and intrinsic factors [20, 141, 192].
2.2.2 Pro-inflammatory signalling
Inflammation can effect signal transduction by an immense variety of path-
ways, both directly and indirectly induced. In the interests of clarity (as well as to
remain within the scope of this work), we focus here on one of the main signalling
cascades that has been implicated in OA pathogenesis (see subsections 2.2.5 and
2.2.8), along with many other inflammatory disease processes: the NF-κB (nuclear
factor kappa-light-chain-enhancer of activated B cells) classical pathway. NF-κB
refers to a family of five transcription factors that exist in almost all cell types
and operate on pro-inflammatory and survival gene targets [105]. Three of the
transcription factors, RELA (or p65), c-REL, and RELB, are transcriptionally
active in their native state. The other two, NF-κB1 (or p105) and NF-κB2 (or
p100) exist as inactive precursors [106].
NF-κB is activated via two separate pathways: the classical and the alternate.
The classical pathway is activated by phosphorylation of IκB by the IKK complex,
which triggers the ubiquitination and degradation of IκB. This allows the active
subunit(s) to be phosphorylated and translocated to the nucleus, where they bind
to their target DNA binding sites [59, 224]. This pathway is often activated by in-
jury and/or inflammation, which causes the release of two first-response cytokines:
IL-1β and TNF-α. These mediators bind to their receptors, which activate the
IKK complex via second messenger signalling (Figure 2.3). With regard to OA
pathogenesis, downstream genes activated by NF-κB include PTGS2, inducible
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nitric oxide synthase (NOS2 ), and MMP1 [183]. The alternate pathway involves
inducible processing of p100. Activation of NIK and the IKK complex lead to p100
phosphorylation and eventual cleavage to p52. RELB and p52 form heterodimers
which then translocate to the nucleus [105, 106, 224].
Parenthetically, the NF-κB system has been a target for much drug devel-
opment [106]. However, since it has an important physiological role in immune
system activation, indiscriminate inhibition could lead to undesired results [121].
Xu et al. [224] argue that a more complete understanding of the molecular mech-
anisms of the specific inhibitors will lead to more targeted therapies. This author
would add that local therapy, as opposed to systemic treatment, should be consid-
ered as well, in order to avoid undesired side effects. (We argue for this approach
below in section 5.2 with regard to our treatment strategy.)
2.2.3 Endothelial molecules in OA inflammation and pain
Endothelial mediators allow inflammation to occur, by vasoactivation and per-
meabilization of the vascular wall. As discussed above, one of the cardinal signs
of inflammation is pain sensation, which occurs due to nociceptor activation by
inflammatory mediators [112, 123]. Specific to OA, endothelial mediators can
influence angiogenesis, which is a disease-modifying process. Pro-inflammatory
cytokine release and inflammatory cell recruitment stimulate angiogenesis in syn-
ovial membrane, cartilage, and bone, thereby contributing to structural changes.
This is accompanied by neoinnervation, which leads to joint nociceptor sensitiza-
tion and deep joint pain [13, 28].
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Figure 2.3: Classical NF-κB (p50/p65) pathways. From the GeneGlobe Pathway Atlas [169]. c©2010
Qiagen, all rights reserved.
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We discuss two endothelial mediators of interest, which represent two vascular
regulation systems: endothelin, in the renin-angiotensin-aldosterone system [185];
and bradykinin, in the kallikrein-kinin system [177]. These systems may cross-talk
[196], which gives rise to our hypothesis (section 2.4 below) that endothelin and
bradykinin receptors may be relevant therapeutic targets in OA.
2.2.4 Endothelin-1
Endothelin-1 (ET-1) is a 21-amino-acid potent vasoconstrictor peptide, mainly
known for its role in maintaining vascular homeostasis. First isolated and charac-
terized in 1988 [227], ET-1 has been implicated in a wide variety of pathologies,
ranging from cardiovascular disorders to lung disease; most often, ET-1 acts in a
pro-inflammatory role. In joint tissues, it is synthesized and released by endothe-
lial cells, synoviocytes, and chondrocytes [146, 230]. It is of interest that ET-1
production can be induced by shearing force, which occurs in an OA joint with
abnormal biomechanical loading.
The author’s laboratory has previously shown that ET-1 plays a major role in
OA pathogenesis. It reduces cartilage anabolism by inhibiting collagen type II and
proteoglycan synthesis via NO mediation in a concentration-dependent manner
[109]: chondrocytes treated with ET-1 and an iNOS inhibitor synthesized more
proteoglycans and collagen than cells treated with ET-1 alone. This effect was
reversed on both gene and protein levels by treatment with a NO donor. ET-1 is
up-regulated in OA tissues, where it promotes MMP-1 and MMP-13 synthesis and
activation, along with an increase in type II collagen neoepitopes and a decrease
23
in TIMP activity [187]. These effects occur via activation of the MAPK and
AKT/PKB pathways, as detected by increased kinase phosphorylation. ET-1
also causes excessive production of NO, which is generated as the result of an
increase in iNOS levels [132]. These effects occur mainly via endothelin receptor
type A (ETA) [110].
2.2.5 Endothelin receptors
ET-1 has two receptor subtypes, A (ETA) and B (ETB). Both G-protein-
coupled receptors (GPCRs), they are differentially expressed in various tissue
types. The classical distribution of ET receptors is as follows: ETA is found in
vascular smooth muscle, where it mediates ET-induced vasoconstriction; ETB is
expressed predominantly in endothelial cells, where it mediates vasodilatation by
the generation of prostaglandins and nitric oxide (NO) [53]. ETB may act as a
clearance receptor for ET-1, thereby minimizing ETA activation, since ETB binds
and remove ET-1 from circulation [26]. Both receptor subtypes are also found in
the central nervous system, where they play a neuromodulatory role [40]. ETA is
expressed in articular tissue by chondrocytes, synoviocytes, and endothelial cells,
where it plays a significant role in cartilage and bone metabolism [124, 144]. ETA
also potentiates inflammatory joint pain induced by ET-1 [52, 111].
ETA signals through Gq/11 and G12/13, activating the PLC, PKC, and PI3-
K pathways (Figure 2.4) [42, 49, 77, 134, 191]. It also activates MAPK path-
ways via intracellular calcium release, and AKT/PKB, downstream of PI3-K ac-
tivation [29]. ETB activates Gi and Gq/11 in smooth muscle and endothelium
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[49, 77, 134, 191]. Chen et al. [42] note that since ET-1 ligates both receptor
subtypes, downstream signalling may cross-talk in both normal and pathological
conditions; however, little is known about this. Similar to the downstream events
of bradykinin receptor ligation (described in subsection 2.2.8), the downstream
signalling pathways activated by ETA can influence early OA pathogenesis by
causing chondocyte hypertrophy, MMP synthesis, and NF-κB activation.
2.2.6 ET-1 and inflammation in OA
ET-1 plays a pro-inflammatory role in articular cartilage catabolism in OA. It
has been detected in the synovial fluid and plasma of both OA and rheumatoid
arthritis (RA) patients at levels at least twice as high as healthy controls (on the
order of 20 pg/mL for OA patients versus 1-10 pg/mL for controls) [152, 230].
ET-1 is also implicated in pain and hyperalgesia [90]. It functions as a nocicep-
tive sensitizer: intradermal injection of ET-1 induces hyperalgesia in the human
forearm [69] and rat hindpaw [89]. It can also cause overt pain: intra-articular
injection of ET-1 induced knee joint inflammation in an animal model [52]. In this
study, selective ETA antagonist treatment reduced nociception and joint inflam-
mation caused by ET-1, carrageenan, or bacterial lipopolysaccharide. Conversely,
treatment with an antagonist selective for ETB or a mixed ETA/ETB antagonist
did not reduce ET-1-induced inflammation, but did reduce carrageenan-induced
inflammation. Thus, ET-1/ETA signalling is implicated in articular nociception.
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Figure 2.4: ET receptor signalling pathways. From the GeneGlobe Pathway Atlas [169]. c©2010
Qiagen, all rights reserved.
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2.2.7 Bradykinin
Bradykinin (BK), a nonapeptide, is one of the most potent endogenous va-
sodilators known. It was identified in 1949 as being released from plasma glob-
ulin upon treatment with snake venoms and trypsin [180]. This release is due
to the proteolytic cleavage of high-molecular-weight kininogen by kallikrein in a
positive-feedback manner [177]. The main physiological roles of the kallikrein-
kinin system, apart from its pro-inflammatory functions, are to regulate blood
pressure and sodium homeostasis by influencing vascular tone [51, 107, 228]. The
kallikrein-kinin system also helps to assemble clotting factors in the contact acti-
vation or intrinsic pathway of coagulation [37]. BK also has roles in inflammation
and nociception: it has been identified as a pro-algesic factor in human inflamma-
tory exudates [11]. BK is generated in all inflamed tissue [204], where it induces
pain through nociceptor sensitization and activation [147]. As we discuss below
(subsection 2.2.9), BK receptors are essential for this process: gene knockout
models deficient for either BK receptor B1 (BKB1) or BK receptor B2 (BKB2)
have reduced nociceptive ability [165, 188]. Specific to OA, BK is generated in
OA synovial membrane and fluid; it also is released due to the increased vascular
pressure in subchondral bone [142].
2.2.8 Bradykinin receptors
Bradykinin ligates two receptors, bradykinin receptor B1 and bradykinin re-
ceptor B2. Both GPCRs, they are expressed in many tissue types, but differ in
expression levels based upon the tissue state. BKB2 is expressed constitutively
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to a large extent in healthy tissue, and is primarily involved in the acute phase
of inflammation [85, 149]. Conversely, BKB1 is only expressed in inflamed tissue:
it is synthesized de novo following tissue injury [204]. BKB1 is also up-regulated
in chronic inflammatory conditions (Figure 2.5), its expression often induced sec-
ondary to inflammatory mediator release [34, 35, 85]. The author’s laboratory
has detected BKB1 expression in human OA synovial membrane and cartilage by
immunohistochemistry (Charlotte Zaouter, unpublished results).
Figure 2.5: Upstream signalling molecules that may lead to BKB1 up-regulation include MAPKs,
PKC, and PI3-K, which modulate transcriptional factors such as NF-κB, AP-1, and CREB that are
involved in BKB1 gene expression. From Calixto et al. [35].
BK receptors generally signal through Gq [81, 118], though they also interact
with Gs [122] and Gi [64, 226] (Figure 2.6). Gq/11 coupling eventually activates the
PI3-K and PKC pathways. As well, Gi coupling leads to PLA2 activation, which
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results in prostaglandin production [226]. With regard to early OA pathogenesis,
the PI3-K pathway activation can cause chondrocyte hypertrophy via AKT/PKB
[208]. The PKC pathway activates downstream catabolic factors such as MMPs
[94, 205, 214, 229] in OA chondrocytes; LaVallie et al. [119] suggest that atypical
PKCζ potentiates NF-κB activation in OA chondrocytes via TNF-α and IL-1β.
2.2.9 BKB1, inflammation, and nociception in OA
It has been suggested that BK, via BKB1 signalling, plays a role in local
tissue injury, pro-inflammatory reactions [23], and nociception [68]. Sainz et al.
[189] have shown that, in an animal model of induced inflammatory arthritis,
BK influences chronic inflammation through ligation of both BKB1 and BKB2.
BKB2 appeared to be principally involved in the acute phase of inflammation
by facilitating leukocyte activation (CD11b), homing (CD44), and transmigration
(CD54). Treatment with a BKB2 antagonist did not affect disease evolution. In
chronic RA, excessive release of kinins in the synovial fluid can produce oedema,
pain, and loss of joint function due to activation of both BKB1 and BKB2 [36].
BKB1 also potentiates the effects of other pro-inflammatory mediators such as
cytokines (IL-β, TNF-α), prostaglandins (PGE2), and transcription factors (NF-
κB). In OA, these mediators are capable of inducing bone and cartilage damage,
synovial tissue hypertrophy, angiogenesis, and inflammatory cell infiltration [22].
BKB2, though it has been implicated in nociceptor sensitization in OA [142,
206], may be less relevant as a therapeutic target in the context of a chronic
inflammatory response.
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Figure 2.6: BK receptor signalling pathways. From the GeneGlobe Pathway Atlas [169]. c©2010
Qiagen, all rights reserved.
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2.3 Animal models of osteoarthritis
Since we used a surgically induced rat model of OA to test our hypothesis (see
section 2.4), we provide an overview of animal models of OA, and focus on joint
pain assessment techniques.
2.3.1 Overview
Animal models of OA fall into three main categories: spontaneous, chemically
induced, or mechanically induced [8, 33]. All these approaches share the goal of
inducing articular degradation in the targeted joint, such that the final outcome
is OA histopathology as examined by serial sectioning [138]. This is commonly
evaluated by scoring using a histopathology assessment system which rates the
severity of histological disease progression and the extent of joint tissue involve-
ment. One such score that is now in common use is the OARSI (Osteoarthritis
Research Society International) histopathology assessment system [168]. Animal
models have elucidated many aspects of OA [212], but one must be careful not
to over-interpret results, since (most) people are not animals: joint biomechanics
and metabolism, as well as musculoskeletal growth patterns, differ significantly
[33]. However, they remain the gold standard for preclinical studies.
Spontaneous OA models are species- and strain-specific. Often arising from
a genetic disposition towards OA, such as type II or type IX collagen mutations
in mice [72, 153], these models are highly variable in terms of their kinetics and
prevalence. To take the example of a model that the author had initially consid-
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ered using in his thesis project, 85% of STR/ort male mice will develop medial
tibial plateau OA between 8 and 30 weeks of age [138]. These models are valuable
to study the genetic and developmental factors involved in OA, since the kinetics
of pathogenesis are probably closest to the human disease. The main advantages
to these models are that the aetiology of OA is known, and that disease severity
and incidence can be controlled to a certain extent [231].
Chemically induced OA models cause joint degradation by intra-articular injec-
tion of pro-inflammatory or degradative substances. Pathogenesis is often rapid,
with significant articular changes and associated pathophysiology detectable within
3-7 days after injection, to take the case of monoiodoacetate injection into the rat
knee [31]. Other common approaches include injections of papain, collagenase,
and hypertonic saline. This class of model can be reproduced in essentially all
of the species commonly used in musculoskeletal research: rodents, rabbits, dogs,
guinea pigs, and so on [33].
Mechanically induced OA models cause OA by physically destabilizing the tar-
get joint. The most common approaches are surgical anterior cruciate transection
and/or meniscectomy in the knee, due to its surgical accessibility and well charac-
terized biomechanics. Joint immobilization [86] or denervation [129] are used less
frequently. Initially reported in large-animal models such as dogs [75], this class
of models has been adapted to small-animal studies more recently [9]. The disease
kinetics are rapid and consistent, and reproduce post-traumatic OA [21, 219]. The
main critique of this approach is that the pathology produced is actually more
severe, and thus not directly comparable, to human OA, which is focal for the
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most part; nonetheless, this varies enormously depending on the specific model.
As described below in section 3.1, we chose a surgically induced OA model for our
study upon expert recommendation (Gordon Ng PhD, personal communication).
2.3.2 Pain assessment in animal OA models
Classically, animal models of OA have focused on cartilage degradation, histo-
pathological changes, and molecular aetiology. More recently, researchers have
become increasingly interested in joint pain and functional limitations of OA as
reproduced in animals. There are relatively few reports of pain assessment in OA
animal models, given their established role in OA research (perhaps because pain
specialists and orthopaedists do not communicate enough!), but the musculoskele-
tal research community is becoming more cognizant of the potential benefits of
functional pain measurement.
Most pain assessment methods focus on OA induced in an animal knee, since
it is an easily accessible joint with well-characterized biomechanics in both labo-
ratory animals and humans; current methodological approaches are comprehen-
sively reviewed by Neugebauer et al. [155]. Pain measurement can be divided into
two modalities: direct assessment, which measures actual joint pain; and indirect
assessment, which measures behaviours affected by joint pain. Most classic modal-
ities are indirect, since they are somewhat easier to implement. As well, they may
be more informative than direct modalities, since the functional limitations of OA
motivate most patient complaints.
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2.3.2.1 Indirect assessment
Common indirect assessments include weight bearing, posture and gait anal-
ysis, and spontaneous mobility. Weight bearing can be subdivided into two cate-
gories: static weight bearing (our modality of choice: see section 3.3.3), where the
animal is stationary, and dynamic weight bearing, where the animal is moving.
Both investigate the weight distribution of the animal by quantifying the force
applied by the limbs; a healthy animal will bear weight roughly equivalently on
their limbs, an animal experiencing limb pain will shift their weight to their other
limb(s). This postural imbalance can be quantified in terms of percent weight
[167], or difference in weight distribution change between treatment and experi-
mental groups [31], to name two of the most popular approaches. Static weight
bearing in rodents is often restricted to the hind limbs for practical reasons: it is
easier to force a rat to rear in a restraint than to restrain it horizontally without
allowing motion. However, since the animal is confined in a stationary artificial
posture, static weight bearing has come under criticism, since animals rarely natu-
rally adopt such a position for long periods of time. Furthermore, it does not take
the shift of weight distribution to the forelimbs into account. Dynamic weight
bearing, as the name suggests, occurs in an open-field environment which allows
the animal to move freely [46]. One critique of this method is that since animals
are required to move, the results can be influenced by the animal’s motivation.
Posture and gait analysis are related to weight bearing assays, in that they
attempt to quantify standing and walking behaviour using subjective rating scales
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in order to calculate an integrated pain score [163]. Behaviours such as foot pad
touch, limping, guarding, eversion, and avoiding contact with the affected limb,
are all assessed and rated by direct observation. Hind paw elevation time and paw
contact time can also be objectively measured by forced ambulation: rodents are
placed on a rotating drum with sensor arrays wrapped around the surface, and
limb use is monitored electronically [91]. The main advantage to such techniques is
that they are used in clinical practice; it is thus easy to“compare” results obtained
with animals to human functional tests (as well, it is simpler for clinicians to
understand researchers’ results using these techniques!).
Open-field activity monitoring, first described as simple observation of an ani-
mal’s motion, velocity, rearing, and so on, in an open field [83, 84], has undergone
a technological revolution in recent years. In-cage activity monitoring, now de
rigueur, involves placing the animal’s home cage in a frame that can either re-
ceive signals from an implanted radio transmitter, or can track motion via infrared
photo-beams [74, 155]. The resulting data, from either high- or low-technology
instrumentation, can be related to pain behaviour in terms of level of activity:
animals in pain will move less and rest more.
Mechanical sensitivity of the distal paw represents a widespread and classic
set of modalities to assess limb hyperalgesia. The distal paw is stimulated with
increasing pressure stimuli, applied either with von Frey filaments (thin nylon
monofilaments of increasing stiffness) to the plantar surface [30, 67] or a Randall-
Selitto algesiometer (a wedge-shaped compressive probe) to the dorsal surface
[172], and paw withdrawal thresholds are measured. Heat stimulus can also be
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applied by infrared apparatus, hot plate, or hot water [96, 198, 199]. Animals with
hyperalgesia will have lower pain thresholds and will withdraw their paw faster
than healthy animals, given the same painful stimulus. These methods, while
valuable in the context of diffuse neuropathic pain models, are rather unrelated,
in our opinion, to knee joint OA. This is concurrent with expert advice (Geoffrey
Bove DC PhD, personal communication), since OA pain is deep joint pain, and
these tests measure secondary hyperalgesia, which is uncommon in human patients
[167]. Furthermore, von Frey filaments, while widely accepted in the pain research
field, have been recently criticized for the inconsistency and experimenter bias
inherent in the method. As well, doubts have arisen as to whether von Frey
filaments are testing a pain modality or an itch modality, especially with lower
filament stiffnesses [30].
2.3.2.2 Direct assessment
More recent reports of joint pain assessment in animals use direct modali-
ties that measure actual joint pain. While these tests are often more difficult
to perform, and interpretation of results more subjective in nature, relative to
indirect modalities, the data obtained is directly related to perception of OA
deep joint pain. This information can prove valuable in assessing the effects of
potential treatments. Perhaps the most intuitive of these methods is direct com-
pression of an arthritic knee joint, which measures mechanical sensitivity. The
joint is squeezed on the medio-lateral axis, and the force required to elicit a
hind limb withdrawal reflex and/or vocalization is measured qualitatively (i.e.
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light squeeze, medium squeeze, high pressure) [73] or quantitatively by calibrated
forceps equipped with strain gauges that measure applied force at the tips and
provide a digital read-out [127, 197, 232]. Animals with joint pain will have lower
withdrawal thresholds; they will withdraw their paw in response to lower com-
pressive forces than healthy animals. This technique, using calibrated forceps,
was initially considered by this investigator, but was discarded in favour of static
weight bearing upon expert advice (Ste´phane Faubert DVM, personal communi-
cation) due to its high degree of invasiveness and subjective nature: the animal
must remain in a very uncomfortable manual restraint for the test, and scoring a
positive pain response is highly subjective.
Mechanical sensitivity has also been assessed by measuring the struggle thresh-
old angle or range of motion, which is decreased in an arthritic joint [193, 232].
While the femur is maintained motionless, the tibia is extended until the animal
struggles. The extension distance that the heel travels during movement is mea-
sured, and is used to calculate the extension angle by trigonometry. By defining
the length of the tibia as the two sides of a triangle which are adjacent to the
angle, and the distance travelled by the heel as the third side, which is opposite
the angle, the cosine law is applied to solve for the angle. (This author would
be concerned about measurement errors, due to the relatively small dimensions
involved!).
Han and Neugebauer [87, 88] have developed an apparatus with a recording
chamber connected to a computerized analysis system to measure and quantify
the painful vocalizations evoked by joint compression. Rodent vocalizations in the
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audible range represent a defence mechanism, and ultrasonic vocalizations in the
22 kHz range reflect an emotional response. Upon knee joint compression (using
the calibrated forceps described above), both the vocalizations evoked during the
stimulation, and those that outlast the stimulation, are recorded and analyzed. In
rats with arthritic knee joints, the rate and duration of vocalizations are increased,
and the compressive threshold required to elicit vocalizations is decreased, as
compared to healthy controls. Neugebaueur et al. [155] suggest an interesting
line of future research: since vocalization during stimulation and vocalization
after stimulation are generated by different neural mechanisms, analyzing which
stimuli cause which set of vocalization responses could help decipher the neural
components of arthritic pain perception.
2.4 Hypothesis and objectives
The author’s laboratory has previously shown (as described above in subsec-
tion 2.2.4) that ET-1 plays a central role in joint tissue metabolism, and has a
catabolic function in matrix degradation in OA. These effects occur primarily
through ligation of ETA. We hypothesize that ET-1 signalling, via ETA, up-
regulates BKB1 expression and BK release in OA tissues, and that this engenders
a vicious cycle of synovial membrane inflammation, articular cartilage destruc-
tion, and joint pain. Therefore, we view these receptors, taken together, as novel
therapeutic targets in OA. We propose that antagonism of these receptors (treat-
ment with specific peptide antagonists of ETA and/or BKB1) may represent a
novel therapeutic option to alleviate, and perhaps prevent or reverse, the pain,
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inflammation, and tissue damage that occur as OA progresses from an acute to a
chronic state. We hypothesize that ETA and BKB1 antagonism will diminish OA
progress and joint pain, with dual antagonism acting in an additive manner.
There were three main objectives of the author’s Master’s research project.
Since the laboratory had no previous experience with OA animal models, nor
with pain measurement, he was tasked to develop and optimize an animal model
of OA, and to design and validate an in vivo pain measurement modality. His
project culminated with a preclinical animal study to test the efficacy of ETA and
BKB1 antagonism at reducing OA joint pain, radiological indices of disease, and
histopathology.
CHAPTER 3
MATERIALS AND METHODS
3.1 Animal model of osteoarthritis
Originally, we had planned to use the STR/ort spontaneous mouse model
of OA [138] (a kind offer from Alain Moreau PhD, director of the Viscogliosi
Laboratory for Molecular Genetics of Musculoskeletal Disorders, at Sainte-Justine
Hospital Research Centre), but severe strain reproduction problems, as well as
confusion about the precise method of pain assessment to be used that would be
appropriate for mice, given their small physique, led us to choose a rat surgical
model of OA, which is described below. This model has several advantages that
proved attractive to us: rapid and reproducible disease kinetics, the ability to
examine histopathology of the entire affected joint, along with well-characterized
and validated methods to measure hind limb pain.
3.1.1 Animals
Eight-week-old male Lewis rats were purchased from Charles River Canada
(Saint-Constant, QC) and housed under standard conditions. All procedures were
approved by the Sainte-Justine Hospital Research Centre animal ethics committee
and conformed to Canadian Council on Animal Care guidelines [160].
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3.1.2 Study design
The study was conducted as a fractional factorial experiment, which is defined
as a judicious selection of a subset of the treatment combinations required for
the complete factorial experiment [7]. That is, a fractional factorial experiment
only tests some carefully selected treatment combinations, as opposed to every
possible combination. These experimental designs are usually employed to exclude
superfluous factor-level combinations, thereby maximizing limited resources, when
the interaction terms in the statistical model are assumed to be negligible as
compared to the main effects terms [154].
Animals were randomly assigned to one of three surgery conditions: anterior
cruciate ligament transection (ACLT), sham surgery, or no surgery (negative con-
trol). Subsequently, animals were assigned to one of four treatment groups, as
detailed below (Table 3.I). Sample size was n = 4 per group. This small sample
size was mandated by the Sainte-Justine Hospital Research Centre animal ethics
committee due to the pilot nature of the study, since we had no previous data
whatsoever with regard to this animal model.
Table 3.I: Experimental groups. Six experimental groups were designated in the fractional factorial
study, with 4 subjects per group.
Group Number Surgery Treatment
1 None Saline
2 Sham Saline
3 ACLT Saline
4 ACLT BQ-123
5 ACLT R-954
6 ACLT BQ-123+R-954
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3.1.3 Surgical technique
OA was induced by surgical transection of the right anterior cruciate ligament.
The procedure was modified from previously published reports [9, 92, 202, 222].
Animals were anaesthetized with inhaled isoflurane (3% / L O2 induction in cham-
ber, 2% / L O2 maintenance with face-mask), and prepared for surgery by clipping
the hair over the ventral and medial aspects of the right leg from hindpaw to hip.
The skin was disinfected with povidone-iodine, and a 3-cm incision was made
medial to the patellar tendon (Figure 3.1A). The subcutaneous tissue and muscle
were then incised and the patella laterally sublaxed; the joint capsule was opened
with the limb hyperextended (Figure 3.1B). With the limb in full flexion, the
anterior cruciate ligament was visualized by blunt dissection, and sectioned by a
latero-medial cut parallel to the tibial plateau, using a #11 scalpel blade (Figure
3.1C-D). Transection was confirmed with the anterior drawer test (Figure 3.1E-F:
E depicts the knee before, and F shows an anterior drawer). The patella was then
replaced, and the limb extended (Figure 3.1G). The joint capsule (Figure 3.1H)
and muscle layers (Figure 3.1I) were closed with 4-0 polygalactin absorbable su-
ture (horizontal mattress stitch, Figure 3.1J). 50 µL of lidocaine was then injected
into the joint capsule to provide local analgesia. Skin was closed with steel surgi-
cal staples (Figure 3.1K). Post-operative hydration (6 mL/kg saline) and systemic
analgesia (0.1 mg/kg buprenorphine HCl) were provided by subcutaneous injec-
tion. Surgical staples were removed 14 days post-operatively (Figure 3.1L). Sham
surgery consisted of all of the above except ligament transection.
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Figure 3.1: Rat ACLT surgical steps. Photos were taken with a 300-mm macro lens (approximate
magnification 2×).
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3.2 Drug treatment
Over the course of two months post-operatively, animals were treated by
weekly intra-articular injections of ETA and/or BKB1 specific peptide antago-
nists: BQ-123 (ETA antagonist; Sigma-Aldrich, Oakville, ON) [98, 99], R-954
(BKB1 antagonist; kind gift from Pierre Sirois, IPS The´rapeutique, Sherbrooke,
QC) [70, 156], both, or saline vehicle, was injected into the right knee at a dose of
30 nmol in a volume of 50 µL. Injections were performed under isoflurane anaesthe-
sia, using a 28G needle (Figure 3.2). Chemical structures are depicted in Figure
A B
C D
Figure 3.2: Intra-articular injection into the rat knee. A, the shaved knee is maintained in extension.
B, the needle is inserted under the patellar tendon into the joint space. C, the syringe plunger is
depressed slowly. D, successful injection is detected by a momentary swelling of the articular space.
Photos were taken with a 300-mm macro lens (approximate magnification 2×).
3.3. Doses were based upon previously published reports [52, 206] of the same
dosages, by intra-articular injection, in studies of acute ET-1- and BK-mediated
pain in the rat knee joint.
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BQ-123 R-954
Figure 3.3: Receptor antagonist chemical structures. Left, BQ-123 (ETA antagonist); right, R-954
(BKB1 antagonist).
3.3 Static weight bearing
3.3.1 Reverse-engineering and design
A static weight bearing apparatus was reverse-engineered from previously pub-
lished reports [31, 32, 213] as described below. We undertook this process because
commercially available apparatuses are not very precise and restrict measurement
paradigms to a few pre-programmed routines. Furthermore, they are prohibitively
costly. Due to our selection of a more precise measurement strategy, our apparatus
is roughly three times as precise as those on the market. It is also cheaper, costing
about half as much as apparatus currently sold. Finally, the software allows for
tremendous flexibility in designing test programs.
3.3.1.1 General features
The basic principle of the static weight bearing test is that a healthy animal
will distribute its weight roughly equally over its hind limbs, and that any shift in
this equilibrium, due to a traumatic intervention, is considered a pain response.
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Rescue due to treatment will result in a return to an even weight distribution
pattern [213]. A static weight bearing apparatus must therefore detect and record
the applied force (weight) on both hind limbs of a rat standing in the apparatus.
As such, the four main components of any static weight bearing apparatus are a
pair of load cells or force transducers, to detect the vertical component of applied
force on each hind limb of the animal; a support base or system for the apparatus
and electronics; a restraint system for the animal with an inclined plane, to ensure
that it stands on its hind limbs; and a computer interface for data recording.
3.3.1.2 Design process
The restraining box was designed using previously published photographs of
commercially available apparatuses to sketch a prototype. Measurements of ap-
propriate inclination angle, height, and width for the restraining box were con-
ducted on 4-month-old rats (approximate weight 500 g), since our study protocol
called for static weight bearing tests up to 16 weeks of age.
The Futek LSB200 (250 gram) load cell with universal serial bus (USB) 210
interface was selected as the force transducer of choice, due to its easy configura-
bility, plug-and-play USB operability, and preprogrammed software. Appropriate
capacity was estimated from the published growth curves for male Lewis rats from
Charles River Canada [41], which indicate that a four-month-old rat should weigh
between 375-425 grams. We therefore chose sensors with 250-gram capacity for
each hind limb, which is a bit more than half the maximal weight of a four-month-
old Lewis rat: this gives our apparatus an effective maximal capacity of 500 grams.
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This also permits the apparatus to be used with slightly older rats and/or animals
from other strains that have higher average body weights than Lewis rats. (These
sensors are rated to protect against overload at 1000% of maximal calibrated load,
which provides a very large margin of safety.) We then engineered the support
system around it and the restraining box, with a base plate, force platforms for
the feet of the animal, and the restraining box on top. Fully dimensioned scaled
technical drawings (Figure 3.4) for all components were auto-drafted using CATIA
(Computer Aided Three-dimensional Interactive Application) V5R19. Machining
of the base plate, force platforms, and restraining box was performed by Usinage
FB (Le Gardeur, QC). The apparatus was assembled in our laboratory (Figure
3.5) following the technical drawings.
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3.3.2 Software setup
Futek USB software (version 1.1.0.0) was used to set test parameters for the
in vivo pain measurement (subsection 3.3.3) as follows: 4 samples recorded per
second, read-out unit in grams, precision at 3 decimal places, test duration of 30
seconds (Figure 3.6). Test results were automatically saved into comma-separated
variable files.
3.3.3 In vivo pain measurement
Over the course of the study, knee joint pain was evaluated biweekly by the
static weight bearing test [31, 32], which evaluates the hind limb weight distri-
bution: shifts from the operated limb towards the contralateral limb (a weight-
bearing deficit) are taken as a pain measure [213]. After conditioning, animals
were introduced to the apparatus and restrained in a plexiglass chamber with an
angled base, such that each hind paw rested on a separate force plate connected
to a load cell (Figure 3.7). The weight in grams distributed on each hind limb was
recorded by a computer software interface as described above in subsection 3.3.2.
Data were transferred off-line to a personal computer, and the weight bearing on
the right hind limb as a percentage of total weight bearing on both hind limbs
was calculated by the following equation [167]:
% weight on right leg =
weight on right leg
weight on right leg + weight on left leg
× 100
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Figure 3.5: Static weight bearing apparatus assembly. (A) assembled base plate; (B) force platform
underside; (C) rat restraining box (angle view); (D) load cell placement inside force platform; (E)
force platform installation; (F) complete apparatus assembled.
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Figure 3.6: Futek USB software (version 1.1.0.0) screenshot. Parameters were set as described in
subsection 3.3.2. Test depicted is from an ACLT animal: a significant difference can be seen between
the applied weight on the left and right channels.
Measurements were averaged over three 30-second test periods. All values are
given as mean ± s.e.m.
A B C
Figure 3.7: Static weight bearing apparatus with rat positioned for measurements. A, side view; B,
angle view; C, front view.
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3.3.4 Statistics
Static weight bearing data were analyzed by repeated measures analysis of vari-
ance (ANOVA), which compares the global differences between groups of response
profiles measured on the same subjects repeatedly during the study [126, 218].
Test values were taken as the dependent variable and treatment group as the
independent variable, with the animal as the grouping factor. Sphericity was
confirmed with Mauchly’s W test. Tukey multiple comparisons testing was used
to establish significance in between groups, with directionality taken from the
sign of the mean difference. P -values less than 0.05 were considered statistically
significant. Analyses were conducted using R (version 2.11.0) [171].
3.4 Euthanasia and sample preparation
At four or eight weeks post-surgery, animals were sacrificed by cardiac puncture
under deep isoflurane anaesthesia. The right knee was dissected and 40-mm-long
samples were cut using a Stryker 810 oscillating bone saw. Rat knees were stored
in phosphate-buffered saline until scanned by digital micro-X-ray (DX) and/or
micro-magnetic resonance (MR) imaging. Samples were dissected the same day
as the radiological scans.
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3.5 Digital micro-X-ray
3.5.1 Image acquisition
All knee samples were X-rayed using a Faxitron MX-20 specimen X-ray system
(Faxitron X-Ray Corporation, Lincolnshire, IL). Anteroposterior and lateral views
were acquired at 5× magnification (10 × 10 µm pixel size) using a dose of 26 kV
for 6 seconds (Figure 3.8). Images were acquired in DICOM format [56].
Figure 3.8: DX software screenshot (Faxitron SR v1.4.3).
3.5.2 Image analysis and scoring
After acquisition, images were transferred off-line to a Macintosh computer,
and analyzed using OsiriX software (version 3.7.1) [184]. Radiological evidence of
joint degradation was scored by two blinded examiners using an OA radiological
score modified from Clark et al. [45] and Esser et al. [62]. Bone demineralization,
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subchondral bone erosion, and heterotopic ossification were all scored on a scale
from 0 (normal) to 3 (marked degenerative changes), using the criteria presented
below in Table 3.II. Total scores were calculated by summing the individual scores
for each index, with a maximum possible score of 9. Radiological scores were
statistically analyzed by one-way analysis of variance, with total scores taken as
the dependent variable and treatment group as the independent variable. Pairwise
post-hoc testing with Holm correction was used to establish significance in between
treatment groups. P -values less than 0.05 were considered statistically significant.
Analyses were conducted using R (version 2.11.0) [171].
Table 3.II: Rubric for radiological scoring of OA joint degradation on DX views. Modified from Clark
et al. [45] and Esser et al. [62].
Index Score Criteria
Bone demineralization
0 Normal bone mineralization
1 Slight demineralization at joint margins
2 Increasing bone loss
3 Severe osteoporosis and
loss of trabecular structure
Subchondral bone erosion
0 Normal appearance
1 Small irregularities at joint margins
2 Substantial subchondral bone remodelling
3 Multiple severe disruptions
of subchondral surface
Heterotopic ossification
0 None
1 Early marginal osteophytes
2 Increasing sclerosis and bony proliferation
3 Multiple severe osteophytes
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3.6 Micro-magnetic resonance imaging
3.6.1 Image acquisition
A subset of animals were sacrificed four weeks post-operatively and their right
knees were imaged by micro-MR. Imaging was performed using a Bruker Phar-
maScan (Ettlingen, Germany) 7 Tesla MR scanner at the McGill University Small
Animal Imaging Lab (Montreal, QC). Knee samples were placed in a custom-made
support inside a 15-mL centrifuge tube (Figure 3.9), which was then filled with
the MR-inert buffer FC-770 (3M Fluorinert Electronic Liquid). Samples were
A
B
Figure 3.9: MR sample support. Teflon sample support plug (A). Dissected knee fixed in place with
the sample support, inserted in tube, and filled with the MR-inert buffer FC-770 (B).
introduced into a 1H mouse brain radio frequency (RF) coil (inner diameter 22
mm), and centred in the magnet. The RF coil was tuned and matched to the sam-
ple, and the magnet was then shimmed. The system was controlled via Bruker
ParaVision software (version 5.0).
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Positioning was confirmed with a tri-pilot rapid scan (Figure 3.10), which was
then used to place 14 coronal slices (Figure 3.11) for two-dimensional anatomi-
cal scanning of the joint (Figure 3.12) using a rapid acquisition with relaxation
enhancement (RARE) multiecho spin echo pulse sequence (TurboRARE). Scan
parameters were as follows: repetition time (TR) = 3500 ms, echo time (TE) =
36 ms, echo train length (ETL) = 8, slice thickness = 500 µm, acquisition matrix
= 384 × 384, and number of averages = 4. Voxel size was 104.16× 104.16× 500
µm. These scans were then repeated in the sagittal projection (Figure 3.13).
Once these scans were acquired, one 1-mm-thick axial slice was placed in the
centre of the knee joint (Figure 3.14) in order to scan the articular cartilage
with a series of multislice multiecho (MSME) T2-weighted pulse sequences. Scan
parameters were TR = 3500 ms, ETL = 1, acquisition matrix = 192 × 256, with
voxel size of 156.25 × 156.25 × 1000 µm. 16 different TE were used: 10, 20, 30,
40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, and 160 ms (Figure 3.15).
Total scan time was roughly 1 hour per sample. Scan sequences were based
on previously published reports [43].
3.6.2 Image processing and analysis
After acquisition, images were converted to DICOM format [56], transferred
off-line to a Macintosh computer, and analyzed using OsiriX software (version
3.7.1) [184]. Anatomical TurboRARE images were examined for correct depiction
of anatomical features of the knee joint, and to confirm ACLT where applicable.
As well, images were analyzed for signs of cartilage decay, indicated by lower
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Figure 3.10: Tri-pilot scans. The sample was scanned in three planes (axial, sagittal, and coronal),
and cross-hairs, representing the centre of the RF coil, were digitally superimposed in order to check
sample positioning within the magnet. If adjustment was required, the distance was measured in the
control software console and the sample was then physically moved to the correct position; the tri-
pilot scan was then repeated. Scans depicted are from a negative control sample. Montage produced
using NIH ImageJ (version 1.43t) [173].
Figure 3.11: TurboRARE scan geometry. Geometry for the anatomical TurboRARE (rapid acquisition
with relaxation enhancement multiecho spin echo pulse sequence) scans were specified using the tri-
pilot scans as a reference frame. Fourteen 500-µm sliced were overlaid on the knee joint space, and
were positioned to obtain complete coverage of the joint space. Screenshot from the MR control
software (Bruker ParaVision 5.0).
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Figure 3.12: Image montage of the 14 slices obtained in the coronal projection. Images are displayed
in anteroposterior order. Scans depicted are from a negative control sample. Montage produced
using NIH ImageJ (version 1.43t) [173].
Figure 3.13: TurboRARE scans were repeated in the sagittal projection. Images are displayed in
lateromedial order. Scans depicted are from a negative control sample. Montage produced using
NIH ImageJ (version 1.43t) [173].
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Figure 3.14: MSME-T2 scan geometry. One 1-mm thick axial slice was placed in the centre of the
knee joint using the sagittal TurboRARE scans as a reference frame. Slice placement and angle were
adjusted in order to scan the maximum possible amount of articular cartilage. Sixteen multislice
multiecho (MSME) T2-weighted scans with varying echo time were then specified. Screenshot from
the MR control software (Bruker ParaVision 5.0).
signal intensity of the articular surfaces. The MSME-T2 images were aligned
into an image stack, and regions of interest (ROI), corresponding to the articular
cartilage, were manually drawn and propagated throughout the stack (Figure
3.16A). A mean T2 fit map was then automatically generated by fitting the signal
intensity to the spin-spin relaxation signal decay equation
S(TE) = M0 exp−
(
TE
T2
)
where signal intensity S is defined as a function of echo time TE, and is related
to the spin density M0 and the transverse relaxation time T2. The equation was
solved for the mean T2 value over the 16-image stack by using least-squares single-
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Figure 3.15: Image montage of the 16 different MSME-T2 scans with TE (echo time) ranging from
10-160 ms. Images are displayed in order of increasing echo time. Scans depicted are from a negative
control sample. Montage produced using NIH ImageJ (version 1.43t) [173].
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exponential curve-fitting, with initial guesses of M0 = signal intensity at 10 ms and
T2 = 30 ms, in order to guarantee rapid convergence [43]. OsiriX then generated
a T2 fit map graph with regression line and values for T2 and M0 (Figure 3.16B).
A B
Figure 3.16: T2 mapping. Using OsiriX, a ROI was drawn on the axial slice (A), propagated through
the image stack, and signal intensity was calculated. This was then fit to the spin-spin relaxation
signal decay equation and solved to yield a mean T2 value (B). Data depicted is from a negative
control sample.
3.7 Cartilage and bone histomorphology
3.7.1 Decalcified tissue
After radiological examination, half the knee samples were fixed in 10% neutral
buffered formalin for two weeks and then decalcified with RDO Rapid Decalcifier
(Apex Engineering Products, Aurora, Illinois) for three days (3 changes, 24 hours
each). Decalcification was confirmed by the absence of radio-opaque bone signal
on DX (Figure 3.17). Samples were then circulated (70% ethanol, 95% ethanol,
3 baths of 100% ethanol, 3 baths of xylene, and 3 baths of paraffin, 35 hours
total) using a Leica TP 1020 automatic tissue processor (Nußloch, Germany) and
embedded in paraffin. Five-micron sagittal sections were acquired from the middle
of the knee joint using a Leica RM 2145 rotary microtome (Nußloch, Germany).
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A B
Figure 3.17: Decalcification confirmation. Decalcification was verified by DX; images were acquired
as above in section 3.5. A, pre-decalcification; B, post-decalcification (anteroposterior views). Images
are from a negative control sample. There is no radio-opaque signal from bone in B, indicating
complete decalcification.
Histomorphological staining was performed using standard protocols [182]:
slides were deparrafinized in xylene (2 baths), rehydrated in decreasing concentra-
tions of ethanol (two baths of 100%, 90%, 70%, 50%), brought to water, stained
with Fast Green FCF for 2 minutes (which colours collagens green) and Safranin O
for 5 minutes (which colours proteoglycans red), counterstained with hematoxylin
for 4 minutes, dehydrated with increasing concentrations of ethanol (70%, 90%,
2 baths of 100%), cleared in xylene (2 baths), and mounted in Permount. Repre-
sentative digital photomicrographs were acquired with a Leica DM R microscope
(Wetzlar, Germany) fitted with a QImaging Retiga 1300 B camera (Surrey, BC),
controlled by QCapture software (version 2.95.0). All images were captured at
50× magnification and subsequently colour-matched and balanced using Adobe
Photoshop CS3.
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3.7.2 Undecalcified tissue
After radiological examination, half the knee samples were fixed in 10% neu-
tral buffered formalin for two weeks and subsequently processed for undecalcified
hard-tissue histology. Samples were hand-circulated in increasing concentrations
of ethanol (70%, 90%, 2 changes of 100%, 24 hours each), cleared in xylene (3
changes over the course of 8 hours), and infiltrated with progressively increasing
concentrations of benzoyl peroxide in methyl methacrylate (MMA) solution (0%,
1%, 2 changes of 4.5%, 48 hours each). Samples were exposed to vacuum for 2
hours at room temperature, in approximately 30 mL of MMA-4.5% benzoyl per-
oxide per sample, to aid polymerization. Subsequently, samples were stored in
the dark at room temperature for two weeks, until polymerization was complete.
This was done in order to have sample blocks that could be used for hard-tissue
histology–sectioned using a sledge microtome–but we ultimately did not pursue
this assay due to time constraints and (ultimately) successful histomorphological
staining of paraffin sections, as described above in subsection 3.7.1. The blocks
remain in the lab for future use.
3.7.3 Histopathological scoring
Four slides from each condition were scored by two blinded examiners using the
Osteoarthritis Research Society International (OARSI) histopathology assessment
system [168], which assigns numeric values to grade, or depth progression into
cartilage (0-6), and stage, or extent of joint involvement (0-4); multiplying grade
and stage yields a total OA score with a maximum value of 24. Slides were
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examined at 25× magnification and the two indices of joint pathology were rated
using the criteria presented below (Tables 3.III and 3.IV). Scores were averaged
in between the two examiners; inter-examiner variation was within ±5%.
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Table 3.III: Grade, or depth progression into cartilage, OARSI histopathology assessment system.
Adapted from Prizker et al. [168].
Grade (key feature) Associated criteria (tissue reaction)
Grade 0: cartilage mor-
phology intact
Matrix: normal architecture
Cells: intact, appropriate orientation
Grade 1: surface intact Matrix: superficial zone intact, oedema and/or superficial
fibrillation (abrasion), focal superficial matrix condensa-
tion
Cells: death, proliferation (clusters), superficial zone hy-
pertrophy
Reaction must be more than superficial fibrillation only
Grade 2: surface discon-
tinuity
As above
Matrix discontinuity at superficial zone (deep fibrillation)
± Matrix depletion, as detected by loss of Safranin O
staining, in upper 1/3 of cartilage
± Focal perichondronal increased stain (mid zone)
± Disorientation of chondron columns
Cells: death, proliferation (clusters), hypertrophy
Grade 3: vertical fis-
sures (clefts)
As above
Matrix vertical fissures into mid zone, branched fissures
± Loss of Safranin O staining into lower 2/3 of cartilage
(deep zone)
Cells: death, regeneration (clusters), hypertrophy, carti-
lage domains adjacent to fissures
Grade 4: erosion Cartilage matrix loss: delamination of superficial layer,
mid layer cyst formation
Excavation: matrix loss in superficial layer and mid zone
Grade 5: denudation Surface: sclerotic bone or reparative tissue including fi-
brocartilage within denuded surface
Microfracture with repair limited to bone surface
Grade 6: deformation Bone remodelling (more than osteophyte formation only)
Includes: microfracture with fibrocartilaginous and os-
seous repair extending above the previous surface
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Table 3.IV: Stage, or extent of joint involvement, OARSI histopathology assessment system. Adapted
from Prizker et al. [168].
Stage % Involvement (surface, area, volume)
Stage 0 No OA activity seen
Stage 1 < 10%
Stage 2 10− 25%
Stage 3 25− 50%
Stage 4 > 50%
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4.1 Abstract
Introduction: Endothelin-1, the vasocontrictor peptide, influences cartilage me-
tabolism mainly via endothelin receptor type A (ETA). Along with the inflamma-
tory nonapeptide vasodilator bradykinin (BK), which acts via bradykinin receptor
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B1 (BKB1) in chronic inflammatory conditions, these vasoactive factors potenti-
ate joint pain and inflammation. We describe a preclinical study of the efficacy
of treatment of surgically induced osteoarthritis with ETA and/or BKB1 specific
peptide antagonists. We hypothesize that antagonism of both receptors will di-
minish osteoarthritis progress and articular pain in a synergistic manner.
Methods: Osteoarthritis was surgically induced in rats by transection of the right
anterior cruciate ligament. Animals were subsequently treated with weekly intra-
articular injections of specific peptide antagonists of ETA and/or BKB1. Hind
limb pain was measured by static weight bearing for two months post-operatively.
Post-mortem, right knee joints were analyzed radiologically by X-ray and magnetic
resonance, and histologically by the OARSI histopathology assessment system.
Results: Single and dual local antagonist treatment diminished overall limb pain,
and accelerated post-operative recovery, after disease induction. Treatments also
protected joint radiomorphology and histomorphology. Dual ETA/BKB1 antag-
onism was slightly more protective, as measured by radiology and histology.
Conclusions: ETA and BKB1 dual antagonism improves chronic pain and pre-
vents joint cartilage degradation in a surgical model of osteoarthritis. Therefore,
they represent a novel therapeutic strategy: specific receptor dual antagonism
may prove beneficial in disease management.
4.2 Introduction
Osteoarthritis (OA) is characterized by a progressive destruction of articular car-
tilage accompanied by subchondral bone remodelling, osteophyte formation, and
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synovial membrane inflammation [79]. Clinically, this disease progresses slowly
and principally affects the hands and large weight-bearing joints. Pain is the
primary complaint of patients with OA. Its aetiology is multifactorial: subchon-
dral bone can have microfractures, osteophytes can cause stretching of periosteal
nerve endings, ligaments may be stretched, the joint capsule can be inflamed
or distended, the synovium may be inflamed, and muscles may spasm [137]. Fur-
thermore, neo-innervation of joint tissue concurrent with angiogenesis [13, 28] may
contribute to deep joint pain. Further understanding of the molecular mechanisms
behind these effects should provide avenues towards targeted disease-modifying or
-slowing treatments [3, 133].
We have previously shown that endothelin-1 (ET-1), a 21-amino-acid potent vaso-
constrictor peptide, plays a major role in OA pathogenesis. It reduces cartilage
anabolism by inhibiting collagen and proteoglycan synthesis [109]. It causes ma-
trix metalloproteinases 1 and 13 to be synthesized and activated in OA cartilage
[187]. ET-1 also causes excessive production of nitric oxide, which is generated
as the result of an increase in inducible nitric oxide synthase levels [132]. These
effects occur mainly via endothelin receptor type A (ETA) [110]: it is expressed
in articular tissue by chondrocytes, synoviocytes, and endothelial cells, where it
plays a significant role in cartilage and bone metabolism [124, 144]; ETA also
potentiates inflammatory joint pain induced by ET-1 [52, 111].
ET-1 affects vascular homeostasis via the renin-angiotensin-aldosterone system
[185]. Through cross-talk with the kallikrein-kinin system [196], it can also me-
diate kinin-induced pain and inflammation. Bradykinin (BK), the inflammatory
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nonapeptide vasodilator, has also been implicated in OA pain and inflammation.
It is generated in OA synovium, as in all inflamed tissue; it also is released due
to the increased vascular pressure in subchondral bone [142]. BK ligates two
receptors, bradykinin receptor B1 (BKB1) and bradykinin receptor B2 (BKB2).
The effects of BK in OA occur largely via BKB1, a receptor implicated in ar-
ticular nociception [189, 206] and pro-inflammatory reactions [23]. BKB1 also
potentiates the effects of other pro-inflammatory mediators such as cytokines and
prostaglandins. BKB2, though it has been implicated in nociceptor sensitization
in OA [142, 206], may be less relevant as a therapeutic target in the context of
a chronic inflammatory response. It is constitutively expressed to a large extent,
and is primarily involved in the acute phase of inflammation [85, 149]. In contrast,
BKB1 is up-regulated in chronic inflammatory conditions, its expression often in-
duced secondary to inflammatory mediator release [34, 35, 85].
Antagonism of ETA and/or BKB1 may represent a novel therapeutic option to al-
leviate, and perhaps prevent or reverse, the pain, inflammation, and tissue damage
that occur as OA progresses from an acute to a chronic state. We hypothesize that
ETA and BKB1 antagonism will diminish OA progress in a synergistic manner.
In the present work, we describe a preclinical study of the efficacy of treatment
of surgically induced OA with ETA and/or BKB1 peptide antagonists, using an
established rat model of the disease. We found that antagonist treatment dimin-
ished hind limb pain and protected joint radiomorphology and histomorphology.
This demonstrates that ETA and BKB1 dual receptor expression is involved in
OA pathogenesis, and that dual receptor antagonism may prove beneficial in OA
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disease management.
4.3 Materials and methods
4.3.1 Rat model of osteoarthritis
4.3.1.1 Animals
Eight-week-old male Lewis rats were purchased from Charles River Canada (Saint-
Constant, QC) and housed under standard conditions. All procedures were ap-
proved by the Sainte-Justine Hospital Research Centre animal ethics committee
and conformed to Canadian Council on Animal Care guidelines [160].
4.3.1.2 Study design
The study was conducted as a fractional factorial experiment. Animals were
randomly assigned to one of three surgery conditions: anterior cruciate ligament
transection (ACLT), sham surgery, or no surgery (negative control). Subsequently,
animals were assigned to one of four treatment groups, as detailed below (Table
4.I). Sample size was n = 4 per group.
Table 4.I: Experimental groups. Six experimental groups were designated in the fractional factorial
study, with 4 subjects per group.
Group Number Surgery Treatment
1 None Saline
2 Sham Saline
3 ACLT Saline
4 ACLT BQ-123
5 ACLT R-954
6 ACLT BQ-123+R-954
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4.3.1.3 Surgical technique
OA was induced by surgical transection of the right anterior cruciate ligament.
The procedure was modified from previously published reports [9, 92, 202, 222].
Animals were anaesthetized with inhaled isoflurane (3% / L O2 induction in cham-
ber, 2% / L O2 maintenance with face-mask), and prepared for surgery by clipping
the hair over the ventral and medial aspects of the right leg from hindpaw to hip.
The skin was disinfected with povidone-iodine, and a 3-cm incision was made
medial to the patellar tendon (Figure 4.1A). The subcutaneous tissue and mus-
cle were then incised and the patella laterally sublaxed; the joint capsule was
opened with the limb hyperextended (Figure 4.1B). With the limb in full flexion,
the anterior cruciate ligament was visualized by blunt dissection, and sectioned
by a latero-medial cut parallel to the tibial plateau, using a #11 scalpel blade
(Figure 4.1C). Transection was confirmed with the anterior drawer test (Figure
4.1D). The patella was then replaced, and the limb extended. The joint capsule
and muscle layers were closed with 4-0 polygalactin absorbable suture (horizon-
tal mattress stitch) (Figure 4.1E). 50 µL of lidocaine was then injected into the
joint capsule to provide local analgesia. Skin was closed with steel surgical staples
(Figure 4.1F). Post-operative hydration (6 mL/kg saline) and systemic analgesia
(0.1 mg/kg buprenorphine HCl) were provided by subcutaneous injection. Sur-
gical staples were removed 14 days post-operatively (Figure 4.1G). Sham surgery
consisted of all of the above except ligament transection.
75
A B C D
E F G H
Figure 4.1: Rat anterior cruciate transection and intra-articular injection. Rat ACLT surgical steps
(A-G) and intra-articular injection (H). Photos were taken with a 300-mm macro lens (approximate
magnification 2×).
4.3.2 Drug treatment
Over the course of two months post-operatively, animals were treated by weekly
intra-articular injections of ETA and/or BKB1 specific peptide antagonists: BQ-
123 (ETA antagonist; Sigma-Aldrich, Oakville, ON) [98, 99], R-954 (BKB1 antag-
onist; kind gift from Pierre Sirois, IPS The´rapeutique, Sherbrooke, QC) [70, 156],
both, or saline vehicle, was injected into the right knee at a dose of 30 nmol in
a volume of 50 µL. Injections were performed under isoflurane anaesthesia, using
a 28G needle (Figure 4.1H). Chemical structures are depicted in Additional File
4.11.1. Doses were based upon previously published reports [52, 206].
4.3.3 Static weight bearing
Over the course of the study, knee joint pain was evaluated biweekly by the static
weight bearing test. A static weight bearing apparatus was reverse-engineered
from previously published reports [31, 32, 213], designed, and machined by Usi-
nage FB (Le Gardeur, Quebec). Technical drawings and photos are appended in
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Additional Files 4.11.2 and 4.11.3.
After conditioning, animals were introduced to the apparatus and restrained in a
plexiglass chamber with an angled base, such that each hind paw rested on a sepa-
rate force plate connected to a load cell. The weight in grams distributed on each
hind limb was recorded by a computer software interface (Futek USB software
interface version 2.10). Data were transferred off-line to a personal computer, and
the weight bearing on the right hind limb as a percentage of total weight bearing
on both hind limbs was calculated by the following equation[167]:
% weight on right leg =
weight on right leg
weight on right leg + weight on left leg
× 100
Measurements were averaged over three 30-second test periods. All values are
given as mean ± s.e.m.
4.3.3.1 Statistics
Static weight bearing data were analyzed by repeated measures analysis of vari-
ance (ANOVA) [126, 218]. Test values were taken as the dependent variable and
treatment group as the independent variable, with the animal as the grouping fac-
tor. Sphericity was confirmed with Mauchly’s W test. Tukey multiple comparisons
testing was used to establish significance in between groups, with directionality
taken from the sign of the mean difference. P -values less than 0.05 were consid-
ered statistically significant. Analyses were conducted using R (version 2.11.0)
[171].
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4.3.4 Euthanasia and sample preparation
At four or eight weeks post-surgery, animals were sacrificed by cardiac puncture
under deep isoflurane anaesthesia. The right knee was dissected, and 40-mm-long
samples were cut and stored in phosphate-buffered saline until scanned by digital
micro-X-ray (DX) and/or micro-magnetic resonance (MR) imaging. Samples were
dissected the same day as the radiological scans.
4.3.5 Digital micro-X-ray
All knee samples were X-rayed using a Faxitron MX-20 specimen X-ray system
(Faxitron X-Ray Corporation, Lincolnshire, IL). Anteroposterior and lateral views
were acquired at 5× magnification (10 × 10 µm pixel size) using a dose of 26 kV
for 6 seconds. Images were analyzed using OsiriX software (version 3.7.1) [184].
Radiological evidence of joint degradation was scored by two blinded examiners
using an an OA radiological score modified from Clark et al. [45] and Esser
et al. [62]. Bone demineralization, subchondral bone erosion, and heterotopic
ossification were all scored on a scale from 0 (normal) to 3 (marked degenerative
changes). Total scores were calculated by summing the individual scores for each
index, with a maximum possible score of 9.
OA radiological scores were statistically analyzed by one-way analysis of variance,
with total scores taken as the dependent variable and treatment group as the
independent variable. Pairwise post-hoc testing with Holm correction was used to
establish significance in between treatment groups. P -values less than 0.05 were
considered statistically significant. Analyses were conducted using R (version
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2.11.0) [171].
4.3.6 Micro-magnetic resonance imaging
4.3.6.1 Image acquisition
A subset of animals were sacrificed four weeks post-operatively and their right
knees were imaged by micro-MR. Imaging was performed using a Bruker Phar-
maScan (Ettlingen, Germany) 7 Tesla MR scanner at the McGill University Small
Animal Imaging Lab (Montreal, QC). Knee samples were placed in a custom-made
support inside a 15-mL centrifuge tube, which was then filled with the MR-inert
buffer FC-770 (3M Fluorinert Electronic Liquid). Samples were introduced into a
1H mouse brain radio frequency (RF) coil (inner diameter 22 mm), and centred in
the magnet. The RF coil was tuned and matched to the sample, and the magnet
was then shimmed. The system was controlled via Bruker ParaVision software
(version 5.0).
Positioning was confirmed with a tri-pilot rapid scan, which was then used to
place 14 coronal slices for two-dimensional anatomical scanning of the joint us-
ing a rapid acquisition with relaxation enhancement (RARE) multiecho spin echo
pulse sequence (TurboRARE). Scan parameters were as follows: repetition time
(TR) = 3500 ms, echo time (TE) = 36 ms, echo train length (ETL) = 8, slice
thickness = 500 µm, acquisition matrix = 384 × 384, and number of averages =
4. Voxel size was 104.16 × 104.16 × 500 µm. These scans were then repeated in
the sagittal projection.
Once these scans were acquired, one 1-mm-thick axial slice was placed in the
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centre of the knee joint in order to scan the articular cartilage with a series of
multislice multiecho (MSME) T2-weighted pulse sequences. Scan parameters were
TR = 3500 ms, ETL = 1, acquisition matrix = 192 × 256, with voxel size of
156.25× 156.25× 1000 µm. 16 different TE were used: 10, 20, 30, 40, 50, 60, 70,
80, 90, 100, 110, 120, 130, 140, 150, and 160 ms.
Total scan time was roughly 1 hour per sample. Scan sequences were based on
previously published reports [43].
4.3.6.2 Image processing and analysis
After acquisition, images were analyzed using OsiriX software (version 3.7.1) [184].
Anatomical TurboRARE images were examined for correct depiction of anatom-
ical features of the knee joint, and to confirm ACLT where applicable. As well,
images were analyzed for signs of cartilage decay, indicated by lower signal inten-
sity of the articular surfaces. The MSME-T2 images were aligned into an image
stack, and regions of interest, corresponding to the articular cartilage, were man-
ually drawn and propagated throughout the stack. A mean T2 fit map was then
automatically generated by fitting the signal intensity to the spin-spin relaxation
signal decay equation
S(TE) = M0 exp−
(
TE
T2
)
where signal intensity S is defined as a function of echo time TE, and is related
to the spin density M0 and the transverse relaxation time T2. The equation
was solved for the mean T2 value over the 16-image stack by using least-squares
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single-exponential curve-fitting, with initial guesses of M0 = signal intensity at 10
ms and T2 = 30 ms, in order to guarantee rapid convergence [43]. OsiriX then
generated a T2 fit map graph with regression line and values for T2 and M0.
4.3.7 Cartilage and bone histomorphology
After radiological examination, knee samples were fixed in 10% neutral buffered
formalin for two weeks, decalcified with RDO Rapid Decalcifier (Apex Engineering
Products, Aurora, Illinois) for three days, circulated, and embedded in paraffin.
Five-micron sagittal sections were acquired from the middle of the knee joint.
Histomorphological staining was performed as previously described [182]: slides
were deparrafinized, rehydrated, stained with Safranin O (which colours proteo-
glycans red) and Fast Green FCF (which colours collagens green), counterstained
with hematoxylin, dehydrated, cleared, and mounted in Permount. Represen-
tative digital photomicrographs were acquired with a Leica DM R microscope
(Wetzlar, Germany) fitted with a QImaging Retiga 1300 B camera (Surrey, BC),
controlled by QCapture software (version 2.95.0). All images were captured at
50× magnification and subsequently colour-matched and balanced using Adobe
Photoshop CS3.
4.3.7.1 Histopathological scoring
Four slides from each condition were scored by two blinded examiners using the
Osteoarthritis Research Society International (OARSI) histopathology assessment
system [168], which assigns numeric values to grade, or depth progression into
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cartilage (0-6), and stage, or extent of joint involvement (0-4); multiplying grade
and stage yields a total score with a maximum value of 24. Scores were averaged
in between the two examiners; inter-examiner variation was within ±5%.
4.4 Results
4.4.1 Dual antagonism ameliorates OA pain tolerance
To determine the effects of ETA and/or BKB1 local antagonist treatment on no-
ciception in a surgical OA model, the static weight bearing asymmetry of the
animals was measured repeatedly over the course of the study (Figure 4.2). Pre-
operative baseline values for all groups indicated hind limb weight bearing sym-
metry (49.89± 0.42%). Unoperated vehicle-treated animals showed no important
changes in hind limb weight bearing from baseline pre-operative values over the
course of the study, staying roughly within ±4% of even weight distribution.
Sham-operated vehicle-treated animals displayed an initial weight bearing im-
balance 14 days post-operatively (36.47 ± 1.12%), but recovered weight bearing
symmetry quickly thereafter (44.84 ± 0.33% by day 26 post-operatively). ACLT
vehicle-treated animals showed significant weight bearing imbalance two weeks
post-operatively, down to 33.66 ± 2.05% weight on the right leg, suggesting se-
vere nociception. All animals had similar nociceptive tolerance at the last mea-
sured time-point (day 50 post-operatively), indicating nociceptive adaptation, but
drug-treated animals were able to recover faster than saline-treated animals (up
to 40.54± 3.36% weight on right leg by day 33 post-operatively).
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Figure 4.2: Antagonist treatment improves static weight bearing tolerance. Static weight bearing
was measured repeatedly at defined time points over the course of the study. Data are presented
as mean ± s.e.m, per experimental group (n = 4), of weight on the right leg as a percentage of
total weight on both hind limbs. Day 0, baseline pre-operative values. Repeated measures ANOVA
with Tukey post-hoc (Table 4.II) indicated that antagonist treatment significantly ameliorated pain
tolerance in ACLT animals over the study period, as compared to saline-treated positive controls.
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Repeated measures analysis of variance of the static weight bearing data, followed
by Tukey post-hoc hypothesis tests (Table 4.II), demonstrated that treatment
with BQ-123, R-954, or both, significantly ameliorated pain tolerance in ACLT
animals over the study period, as compared to saline-treated positive controls
(0.00192 ≤ P ≤ 0.00713). Sham surgery was found to be slightly less painful
than ACL transection (P = 0.03115), confirming that ACLT is necessary for a
maximal nociceptive response. Furthermore, nociception in the sham-operated
animals was comparable to unoperated animals, with no statistically significant
difference calculated (P = 0.99313).
Table 4.II: Tukey post-hoc tests were conducted following repeated measures ANOVA of the static
weight bearing data using R (version 2.11.0) [171]. From left to right, the table columns present the
contrast of interest, the parameter estimate from the linear matrix model, the standard error of that
estimate, the standard z-score, and the associated P-value.
Contrast Estimate Standard Error z score P(>|z |)
None/Saline vs 6.56489 1.84612 3.556 0.99313
Sham/Saline
Sham/Saline vs 5.78468 1.86531 3.101 0.03115
ACLT/Saline
ACLT/BQ-123 vs -1.23127 1.77364 -0.694 0.00713
ACLT/Saline
ACLT/R-954 vs 1.00281 1.83227 0.547 0.00192
ACLT/Saline
ACLT/BQ-123+R-954 vs 0.97373 1.74878 0.557 0.00211
ACLT/Saline
4.4.2 Dual antagonist treatment improves radiological indices of OA
Right knee joints were dissected at the end of the study period and imaged by
DX (Figure 4.3) and MR (Figure 4.4) to examine the radiological effects of an-
tagonist treatments. ACLT rapidly induced radiological evidence of OA: knee
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joints showed signs of degradation such as subchondral bone remodelling, osteo-
phyte formation (Figure 4.3c and Table 4.III), cartilage layer thinning (Figure
4.4c), and lengthened cartilage T2 (Table 4.IV). Neither sham surgery nor intra-
articular injection affected joint radiomorphology (Figure 4.3a-b and Figure 4.4a-
b). DX analysis of antagonist-treated knee joints showed less subchondral bone
remodelling and heterotopic ossification than saline-treated animals (Figure 4.3d-
f and Table 4.III). Dual ETA/BKB1 antagonism appeared to be slightly more
protective than single antagonism: less subchondral bone remodelling and greater
trabecular integrity was observed in the dual-antagonist-treated animals than in
the single-antagonist-treated animals. Radiological scoring of the DX views for
a panel of OA joint degenerative changes (Table 4.III) demonstrated that treat-
ment with BQ-123, R-954, or both, significantly ameliorated radiological indices
of disease progression in ACLT animals, as compared to saline-treated positive
controls (0.0020 ≤ P ≤ 0.0214, one-way ANOVA with Holm post-hoc). MR anal-
ysis of knee joints revealed that antagonist-treated animals had greater cartilage
thickness and fewer cartilage lesions (Figure 4.4d-f), as well as shorter cartilage
T2 (Table 4.IV, statistical significance not achieved) than saline-treated animals.
These data suggest that antagonist treatment protected joint radiomorphology
after ACLT.
4.4.3 Antagonism protects joint histomorphology
To investigate the effects of ETA and/or BKB1 antagonist treatment on histolog-
ical indices of disease, rat knee joints were processed to assess cartilage proteogly-
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Figure 4.3: Dual antagonist treatment improves radiological indices of OA: X-ray results. A) no
surgery and saline treatment; B) sham surgery and saline treatment; C) ACLT and saline treatment;
D) ACLT and BQ-123 treatment; E) ACLT and R-954 treatment; F) ACLT and BQ-123+R-954 dual
treatment. Blue arrows indicate tibial plateau, purple arrows indicate subchondral bone, and green
arrows indicate osteophytes. Sagittal views. Scale bar, 1 cm.
Table 4.III: Radiological scoring of the DX views of the knee joints indicated that antagonist
treatment protected joint radiomorphology after ACLT. One-way ANOVA with Holm post-hoc: †,
P = 0.0214, ACLT/BQ-123 treatment versus ACLT/saline treatment; ‡, P = 0.0020, ACLT/R-954
treatment versus ACLT/saline treatment; §, P = 0.0125, ACLT/BQ-123+R-954 dual treatment
versus ACLT/saline treatment.
Group Number Surgery Treatment Mean total radiological score
1 None Saline 0.25
2 Sham Saline 1.16
3 ACLT Saline 4.86
4 ACLT BQ-123 2.83 †
5 ACLT R-954 2.50 ‡
6 ACLT BQ-123+R-954 2.67 §
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Figure 4.4: Dual antagonist treatment improves radiological indices of OA: MR results. A) no
surgery and saline treatment; B) sham surgery and saline treatment; C) ACLT and saline treatment;
D) ACLT and BQ-123 treatment; E) ACLT and R-954 treatment; F) ACLT and BQ-123+R-954 dual
treatment. Red arrows indicate articular cartilage. Sagittal views. Scale bar, 1 cm.
Table 4.IV: Cartilage mean T2 values in milliseconds were calculated for all conditions using OsiriX
software (version 3.7.1) [184]. Statistical significance was not achieved.
Group Number Surgery Treatment Mean T2 value (ms)
1 None Saline 51.60
2 Sham Saline 52.12
3 ACLT Saline 64.38
4 ACLT BQ-123 63.23
5 ACLT R-954 61.13
6 ACLT BQ-123+R-954 56.57
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can content and joint histomorphology (Figure 4.5). ACLT sham-treated animals
lost most proteoglycan staining when examined at 8 weeks post-operatively, with
severe articular surface disruptions and osteophyte formation (Figure 4.5c). In
contrast, cartilage proteoglycans were detected in the knees of ETA and/or BKB1
antagonist-treated animals, indicating that treatment protects cartilage structural
components. As well, articular surface integrity was preserved to a greater extent,
with dual antagonism appearing to be most protective (Figure 4.5d-f). Neither
sham surgery nor intra-articular injection affected joint histomorphology (Figure
4.5a-b). Mean OARSI scores (Table 4.V, statistical significance not achieved) in-
dicate that antagonist treatment reduced the amount of affected joint tissue and
the degree of histopathology.
A B C
D E F
Figure 4.5: Antagonist treatment protects joint histomorphometry. A) no surgery and saline treat-
ment; B) sham surgery and saline treatment; C) ACLT and saline treatment; D) ACLT and BQ-123
treatment; E) ACLT and R-954 treatment; F) ACLT and BQ-123+R-954 dual treatment. Yellow
arrows indicate loss of Safranin O staining, purple arrows indicate cartilage notching, and red arrow
indicates an osteophyte. Sagittal sections, Safranin O/Fast Green FCF staining. Scale bar, 200 µm.
Original magnification 50×.
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Table 4.V: OARSI histopathology scores. Four slides per condition were scored by two blinded
examiners using the OARSI histopathology assessment system [168]. Results were averaged and
are presented as mean scores per condition. Inter-examiner variation was within ±5%; statistical
significance not achieved.
Group Number Surgery Treatment OARSI score
1 None Saline 0.43
2 Sham Saline 0.00
3 ACLT Saline 17.00
4 ACLT BQ-123 10.25
5 ACLT R-954 4.25
6 ACLT BQ-123+R-954 3.50
4.5 Discussion
In the present study, we investigated whether antagonism of ETA and/or BKB1
could slow and/or prevent osteoarthritic cartilage degradation and joint pain in a
rat surgical model of OA. We provide several lines of evidence that suggest pro-
tective effects of ETA and BKB1 dual antagonism in vivo: antagonist treatment
improved hind limb pain tolerance, ameliorated radiological indices of disease, and
protected cartilage biochemical integrity and articular cartilage and bone histo-
morphometry.
The most interesting finding of our study is that nociceptive tolerance was aug-
mented in our model after ETA and/or BKB1 antagonist treatment, with faster
post-operative recovery than vehicle-treated controls. These results are consistent
with other reports where local treatment with ETA or BKB1 receptor antagonists
reduced overt acute joint pain [52, 206]. We extend this finding to the dual an-
tagonist treatment approach in a model of chronic pain, as well as relating it to
measures of joint integrity by radiology and histology. Low-grade joint pain is the
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most common reason for patient presentation, and is often the major debilitating
factor in OA cases [60, 65]. Thus, the anti-nociceptive effects of ETA and/or
BKB1 antagonism make this treatment strategy attractive.
We found that single and dual ETA/BKB1 antagonist treatments decreased radi-
ological disease indices, in terms of osteophyte formation, cartilage thinning, and
subchondral bone remodelling, with dual antagonism being most protective. As
well, cartilage T2, increased in ACLT animals, was decreased by antagonist treat-
ment, which indicates a cartilage-preserving effect. Longer cartilage transverse
relaxation times are an indicator of cartilage degradation; this MR parameter is
indicative of cartilage composition and integrity [25, 27, 201]. Radiographic evi-
dence is the main criterion for OA diagnosis and progression [1, 162]. The most
common clinical diagnostic test is via X-ray of the affected joint: joint space nar-
rowing as measured on X-ray is often used as a longitudinal marker of disease
evolution. It is difficult to directly compare radiological parameters between hu-
man and rat knees due to the quadrupedal nature of the animal and the markedly
different radiological anatomy that this entails [216]. However, we were able to
detect radiological evidence of OA progression in ACLT animals, as has been de-
scribed in similar studies [43, 217].
OA induction in rat knees led to a rapid decrease in cartilage proteoglycan stain-
ing, along with articular surface disruption and osteophyte formation [9, 92].
ETA/BKB1 antagonist treatment protected the proteoglycan content of the joint
and preserved articular surface integrity. This allowed the joint cartilage to re-
tain its normal biophysical properties, as cartilage proteoglycans are responsible,
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along with collagen, for retaining water in the tissue, which provides spring and
resilience [151, 186]. These findings likely suggest that the protection of cartilage
proteoglycans and articular surface histomorphology may be one explanation for
the increased pain tolerance observed in antagonist-treated animals; our results
concur with those of other reports, which correlated the preservation of articular
cartilage proteoglycan staining with pain tolerance behaviour [9].
The ET-1 and BK systems are involved in joint tissue inflammation and noci-
ception, concomitant with pro-inflammatory mediators. However, exploration of
potential therapeutic targets in these systems has been modest: the main classes of
disease-modifying osteoarthritis drugs currently in development include cytokine
and matrix metalloproteinase inhibitors, anti-resorptives, and growth factors [170].
To our knowledge, the only clinical trial of a drug targeting a vasoactive factor in
OA is the bradykinin receptor B2 antagonist Icatibant, by Sanofi-Aventis [190].
This drug is no longer in clinical development [174], due to mixed results: while
it provided local analgesia in knee OA, no anti-inflammatory effect could be de-
tected [200]. Our results suggest that ETA and BKB1 represent novel therapeutic
targets in OA. Specific receptor antagonists could be tested in clinical trials for
OA pain and tissue damage.
4.6 Conclusions
Using a rat surgically induced model of OA, we demonstrated that local treat-
ment with specific peptide antagonists of ETA and/or BKB1 may slow or stabilize
the development of radiomorphological and histomorphological changes occurring
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in OA pathogenesis. Furthermore, we showed that antagonist treatment acceler-
ated recovery of, and improved longitudinally, pain tolerance in ACLT animals.
Taken together, our results indicate that blocking ETA and BKB1 improves OA
prognostic indices, which implies that defective signalling might play a role in
chronic OA pain. Our results also raise the possibility of targeted dual receptor
antagonism as a relevant therapeutic option. Further studies are required to un-
derstand the mechanisms underlying the exact nature of receptor cross-regulation
and synergism.
4.7 List of abbreviations
ACLT, anterior cruciate ligament transection; ANOVA, analysis of variance; BK,
bradykinin; BKB1, bradykinin receptor B1; BKB2, bradykinin receptor B2; DX,
digital micro-X-ray; ET-1, endothelin-1; ETA, endothelin receptor type A; ETL,
echo train length; MR, magnetic resonance; MSME, multislice multiecho; OA, os-
teoarthritis; OARSI, Osteoarthritis Research Society International; RARE, rapid
acquisition with relaxation enhancement; RF, radio frequency; TE, echo time;
TR, repetition time.
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CHAPTER 5
DISCUSSION
5.1 Main results of experimental study
In the article manuscript that makes up the previous chapter, we describe a
preclinical study of the efficacy of ETA and BKB1 antagonism at reducing OA
pathology and joint pain in an animal model of OA. We report that local treatment
with specific peptide antagonists of ETA and/or BKB1 was able to slow and/or
prevent early OA pathogenesis in the rat ACLT model of OA, as determined by
pain behaviour assessment, radiological joint examination, and joint histopathol-
ogy. We found that treatment diminished hind limb pain, improved radiological
indices of disease, protected cartilage biochemical integrity, and preserved articu-
lar cartilage and bone histomorphometry.
As noted above, we found that antagonist treatment improved pain tolerance
in ACLT animals. Apart from the operative trauma, it is well-documented that
surgical destabilization of the rat knee joint causes chronic joint pain [32], which
is concurrent with a rapid development of radiographic [217] and histological OA
[9, 92]. Thus, examination of the pain tolerance behaviour in our model appears
to be a valid measure of functional biomechanics. This observed pain reduction
is perhaps the most important result in terms of its impact on clinical therapy:
low-grade joint pain is the most common reason for initial patient complaints in
OA cases [60, 65], and engenders severe functional limitations. De-Melo et al. [52]
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have previously demonstrated that local treatment with ETA antagonists reduces
overt acute joint pain, and similar work by Tonussi et al. [206] has demonstrated
acute pain reduction with BKB1 antagonists. We extend this finding to the dual
antagonist treatment approach in a model of chronic pain, as well as relating it to
measures of joint integrity by radiology and histology. Thus, the anti-nociceptive
effects of ETA and/or BKB1 antagonism make this treatment strategy attractive.
We determined that antagonist treatment decreased radiological indices of OA:
treated animals had fewer osteophytes (if at all), thicker articular cartilage, and
less subchondral bone remodelling. Dual antagonism appeared to be the most
protective treatment strategy. As well, cartilage transverse relaxation time (T2),
which increases in ACLT animals [43], was decreased by antagonist treatment,
which indicates a cartilage-preserving effect. Shorter cartilage transverse relax-
ation times are an indicator of intact articular cartilage and longer times indicate
cartilage degradadion; this MR parameter is indicative of cartilage composition
and integrity [25, 27, 201]. More generally, radiographic evidence is the main cri-
terion for OA diagnosis and progression [1, 162], but is not without controversy as
a prognostic measure (as discussed below). The most common clinical diagnostic
test for OA is an X-ray of the affected joint: joint space narrowing as measured
on X-ray is often used as a longitudinal marker of disease evolution, and osteo-
phyte formation and/or subchondral bone remodelling can be detected. While it
is difficult to directly compare radiological parameters between human and rat
knees due to the quadrupedal nature of the animal and the markedly different
radiological anatomy that this entails [216], we were able to detect radiological
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evidence of OA progression in ACLT animals, as has been described in similar
studies [43, 217].
In terms of joint histopathology, we ascertained that OA induction in rat
knees by ACLT led to a rapid decrease in cartilage proteoglycan staining, along
with articular cartilage surface disruption and osteophyte formation. This con-
firm previous reports [9, 92] of the histopathological findings in similar surgical
OA models in the rat. ETA and/or BKB1 antagonist treatment protected the
proteoglycan content of the joint cartilage to a large extent and preserved ar-
ticular surface integrity, with less cartilage notching and almost no osteophytes
detected upon histological examination. This most likely allowed the joint car-
tilage to retain its normal biophysical properties, as cartilage proteoglycans are
responsible, along with collagen, for retaining water in the tissue, which provides
spring and resilience [151, 186]. We speculate that the protection of cartilage
proteoglycans and articular surface histomorphology may be one explanation for
the increased pain tolerance observed in antagonist-treated animals; our results
concur with those of other reports, which correlated the preservation of articular
cartilage proteoglycan staining with pain tolerance behaviour [9].
5.2 Limitations of study and suggested experimental work
Our study has several limitations, which must colour the interpretation of our
results. Our chosen animal model, rat ACLT, has been critiqued for producing
pathology that is more aggressive than human OA, and thus not entirely repre-
sentative of the disease phenotype as observed in human patients. We chose this
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model because of its rapid and stereotypical disease kinetics, the established and
validated pain measurement modalities available for it, as well as a favourable
cost-benefit ratio. As we suggest below in subsection 6.2.1, large-animal stud-
ies would strengthen our conclusions. However, testing a hypothesis with little
previous in vitro data in an in vivo context represents a high-risk/high-benefit
approach to the problem. As such, potential pitfalls, especially time and financial
constraints, must be carefully considered.
The treatment strategy for our study was selected based upon previously pub-
lished reports, but we did not perform in-vivo dose-response or time-course anal-
yses ourselves to determine the pharmacokinetics and pharmacodynamics in our
system. While we feel our treatment strategy is robust, given the well-established
disease kinetics of our animal model, a full examination of dose-response and
time-course experiments would add to the study, lending more weight to the final
treatment pattern. At the very least, low- and high-dose treatments would allow
dose optimization. This limitation might be partially addressed by in vitro stud-
ies: our laboratory routinely isolates human chondrocytes and synoviocytes from
tibial plateaus of OA patients undergoing total knee arthroplasty [132]. These cells
could be cultured in the presence of the antagonists, and stimulated with ET-1
and/or BK. Downstream cellular responses, such as MAP kinase phosphorylation
or pro-inflammatory gene transcription, could be examined following varying drug
doses and time courses. However, this author would question the relevance of such
an approach, since in vitro assays and in vivo pharmacological effects are due to
two very different sets of phenomena, and it is difficult to extrapolate from one
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to the other. Furthermore, a strict dose-response experiment would be indicated
where the pain phenomenon or the pharmacological approach is completely unex-
plored, with no previous in vivo data. Our strategy is in contrast to such a case,
since both of our drugs and the animal disease model have been extensively stud-
ied; our novel contributions were to extend the existing knowledge to the chronic
joint degeneration condition, and to test the dual-antagonist combined treatment
approach for potential synergistic or additive effects.
Some reviewers of our work had questioned the necessity of a local treatment
strategy, noting (correctly) that patients much prefer oral treatment options, since
they are easier to comply with, and do not necessitate regular physician interven-
tion for injection. We had initially investigated a systemic treatment model, by
implantation of an osmotic mini-pump to deliver drug constantly. However, this
was abandoned for two main reasons. First, we feared that the administration of
antagonists of vasoactive substances would negatively affect blood pressure reg-
ulation. Second, and perhaps more importantly, we wanted to ensure that our
drugs would actually reach and affect the target tissues. Cartilage is avascular,
nourished by diffusion; given the short circulating half-life of small peptides, we
did not think that our drugs would arrive intact after peripheral circulation up-
take, arterial distribution, and then diffusion to the joint cartilage. We preferred
to inject the drugs directly next to the target tissues, in the synovial space. We
did not perform radio-tracer studies, which are de rigueur with novel pharma-
cological agents. However, both our antagonists are well-characterized and have
been used in a number of animal and human clinical studies: thus, a full phar-
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macodynamic/pharmacokinetic study would have unnecessarily repeated previous
work, and would have not added to our results, in the opinion of this author.
Our histological assessment was carried out on decalcified tissues, using stan-
dard histochemical protocols. Such examination of cartilage biopsies or serial
sections of animal knee joints, followed by scoring using a validated assessment sys-
tem, is the gold standard for articular histomorphology [138, 168]. Some reports
have argued for immunohistochemical end-point targets in OA histopathology
assessment, such as staining for proteoglycans, collagens, or aggrecans [15, 38],
claiming that conventional histochemical approaches fail to convey a complete
picture of the disease. This author would view such immunohistochemical assess-
ments as interesting complementary information, but believes that the ease of use
and standardized conditions of classical histochemical techniques make them a
first choice for evaluating OA pathology in an animal model.
Any histological assessment system can be critiqued as follows: histological
scoring of any phenomenon can be an imprecise approach that is often more art
than science. Using well-described and validated systems obviates this concern
somewhat. In this author’s view, the most important features of a histopathology
assessment system are that it assigns numerical indices to at least two different
histological features of a given disease, and that it has detailed criteria to allow for
reproducible scoring. Such systems are robust and can form the basis for quanti-
tative statistical analysis, if sampling size is large enough. It must be noted that
our system of choice, the OARSI histopathology assessment, has been validated
and meets these criteria.
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Pain tolerance in our study was measured by static weight bearing, a cost-
effective and rapid method of assessing hind limb pain in laboratory animals.
However, this is an artificial modality in many senses, since the animal adopts
an unnatural posture and is confined in a stationary restraint for the duration
of the test. There is a considerable amount of controversy in the pain research
field as to the best evaluation for joint pain in animal models [8, 30, 155]. This
investigator had considered von Frey filaments, a modified Randall-Selito test,
pressure application measurements, and direct joint compression, but decided on
static weight bearing following expert recommendations (Geoffrey Bove DC PhD
and Ste´phane Faubert DVM, personal communications). Furthermore, in the
human patient population, improvements in physical function correlate well with
pain relief [16], making biomechanical assessment a priority for our research.
While informative, static weight bearing is generally being phased out in favour
of dynamic weight bearing, an assay where the animal is free-moving in a cage
with a force sensor array on the bottom and a synchronized video camera capture
to score individual limb use and match it to applied force. This allows the animal
to be observed with a natural posture as it moves, giving a more complete picture
of joint pain as it affects behaviour. We had investigated the possibility of reverse-
engineering a dynamic weight bearing apparatus, but it was deemed too costly
and time-consuming. While it is impossible to directly question lab rats as to their
perceived functional impairment, classical behavioural assays such as open-field
activity monitoring [83, 84] might shed light on the behavioural correlates of pain
in our model. Collaboration with pain researchers may be helpful to realize these
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studies; the author has therefore initiated contact with the Alan Edwards Centre
for Research on Pain at McGill University.
Our data indicated that the animals became tolerant of a painful knee joint by
the end of the study period, with values clustering towards a common mean for all
conditions. This author interprets that result as a tolerance phenomenon, whereby
the nociceptive stimulus is perceived less and less over time due to habituation.
Thus, the length of our study, while selected to allow the maximal radio- and
histo-pathogenesis in our chosen model, may be less ideal for nociceptive studies,
due to the potential for the confounding effects of tolerance behaviour.
Radiological examinations of the rat knee joints were only undertaken post-
mortem ex vivo in our study. This allowed us to examine samples at the highest
possible resolution (10× 10 µm pixel size for DX, 104.16× 104.16× 500 µm voxel
size for MR) with very high signal-to-noise ratio, since the samples were scanned
in isolation after dissection. However, this strategy only allows for retrospective
evaluation of joint radiomorphology, and does not permit longitudinal monitoring
and evaluation of disease phenotype and/or treatment effects. Thus, it would
be intriguing to perform in vivo longitudinal MR and/or CT studies, imaging
knee joints at several time-points over the course of the experiment. Moreover,
it has long been established that there is a poor correlation between radiological
evidence of joint degradation and human pain perception [18, 57, 82, 113], which
raises the question: precisely what is being examined via radiological imaging in
animal models of OA?
A complementary project would be to investigate the neurological correlates
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of joint pain by imaging the brain and central nervous system components by
MR (Pascal Vachon DVM, personal communication) to examine central nervous
system changes concurrent with peripheral chronic pain. This line of investigation
is relevant because we and others [67] have demonstrated pain tolerance behaviour
over time in chronic surgical models of OA. The musculoskeletal research axis at
Sainte-Justine Hospital Research Centre has just acquired a SkyScan whole-body
micro-CT machine for rodents, and the author has set up a study protocol with
the McGill Small Animal Imaging Lab for longitudinal MR: it will be interesting
to see the results of these experiments.

CHAPTER 6
CONCLUSIONS AND FUTURE WORK
6.1 Conclusions
Using a rat surgically induced model of OA, we demonstrated that local treat-
ment with specific peptide antagonists of ETA and/or BKB1 may slow or stabilize
the development of radiomorphological and histomorphological changes occurring
in OA pathogenesis. Furthermore, we showed that antagonist treatment acceler-
ated recovery of, and improved longitudinally, pain tolerance in ACLT animals.
Taken together, our results indicate that blocking ETA and BKB1 improves OA
prognostic indices, which implies that defective signalling might play a role in
chronic OA pain. Our results also raise the possibility of targeted dual receptor
antagonism as a relevant therapeutic option. Further studies are required to un-
derstand the mechanisms underlying the exact nature of receptor cross-regulation
and synergism.
6.2 Future research questions
6.2.1 Preclinical in vivo trials
This study opens several potential avenues of investigation. First, the rat
ACLT model of OA and the static weight bearing apparatus represent important
research tools. The robustness and rapid kinetics of the surgical OA model make
it an attractive option for preclinical studies [9, 92]. The static weight bearing
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apparatus is an accepted modality to measure hind limb and joint pain in labo-
ratory rodents [31, 32, 213]. They may be used to test other disease-modifying
OA drugs [170] for pain-lowering efficacy and joint morphology protection in an
accepted preclinical disease model. A priori, this author would suggest the evalu-
ation of other endothelial factor blockers (such as receptor antagonists, signalling
inhibitors, or direct inhibitors), or anti-angiogenic factors, as drugs targeting these
OA disease processes are currently under-represented in Phase II/III clinical trials
[170, 221]. As OA is a multifactorial disease, drugs that target other molecular
processes in OA pathogenesis could also be tested in the same paradigm.
In a similar vein, large-animal studies could be undertaken with our com-
pounds, or with other ETA and/or BKB1 antagonists: surgically induced OA in
the dog [75] is the model of choice for demonstrating efficacy in OA drug develop-
ment. Another approach would be to use ETA and/or BKB1 antagonists to treat
OA as it develops in one or more of the spontaneously occurring animal models.
As the aetiology is usually well-understood in this class of models [231], delaying
or preventing joint disease from developing would add to our understanding of
how ETA and BKB1 antagonism interferes with the molecular pathogenesis of
OA. To discuss a model that the author had initially considered using: if ETA
and BKB1 antagonism protects against the onset of joint disease in male STR/ort
mice, we would be able to suggest that it promotes the increased expression of
protective cytokines TGF-β1 and IL-4 in the articular microenvironment, since
female STR/ort mice develop less OA than males due to increased local expression
of these cytokines in joint tissues at 2 months of age [130].
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6.2.2 In vitro mechanistic studies
The identification of molecular targets for OA treatment is a rapidly expanding
discipline [3]. By taking a reductionist approach, we can investigate the signalling
pathways involved in ETA and/or BKB1 receptor antagonism, thereby elucidating
the molecular mechanisms and downstream effectors responsible for the observed
reduction in disease severity in the rat model. That is to say, we would examine the
effects of ETA and/or BKB1 receptor antagonism on a cellular and molecular level.
We have outlined studies to examine the common PI3-K and NF-κB signalling
pathways engaged by both ET-1 and BK, via ETA and BKB1 (see subsections
2.2.5 and 2.2.8), in human chondrocytes and synoviocytes, building on preliminary
data that shows receptor co-localization in OA synovial tissue. As well, we intend
to examine downstream effector molecule gene expression by RT-qPCR, and pro-
tein production by ELISA, following ET-1 and/or BK stimulation, with or without
single and/or dual antagonist pre-treatment. Targets of interest include: gelati-
nases (MMP-2, MMP-9); collagenases (MMP-1, MMP-13); stromelysin (MMP-3);
aggrecanases (ADAMTS4, ADAMTS5); and pro-inflammatory cytokines (IL-1β,
TNF-α). Finally, by examining ETA and BKB1 receptor gene and protein expres-
sion under these conditions, we hope to determine the precise nature of receptor
cross-up-regulation, to allow a more tailored pharmacological approach based on
the ratio of relative expression. This will also inform the development of second-
generation drugs, including single-molecule approaches.
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